CA2400689C - Infusion site leak detection system and method of using the same - Google Patents
Infusion site leak detection system and method of using the same Download PDFInfo
- Publication number
- CA2400689C CA2400689C CA002400689A CA2400689A CA2400689C CA 2400689 C CA2400689 C CA 2400689C CA 002400689 A CA002400689 A CA 002400689A CA 2400689 A CA2400689 A CA 2400689A CA 2400689 C CA2400689 C CA 2400689C
- Authority
- CA
- Canada
- Prior art keywords
- individual
- fluid
- detection system
- leak detection
- infusion site
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
- A61M5/16831—Monitoring, detecting, signalling or eliminating infusion flow anomalies
- A61M5/16836—Monitoring, detecting, signalling or eliminating infusion flow anomalies by sensing tissue properties at the infusion site, e.g. for detecting infiltration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3306—Optical measuring means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2209/00—Ancillary equipment
- A61M2209/04—Tools for specific apparatus
- A61M2209/045—Tools for specific apparatus for filling, e.g. for filling reservoirs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
- A61M5/14248—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body of the skin patch type
Abstract
An infusion leak detection system indicates that a fluid to be delivered int o an individual's body has leaked near an infusion site. The infusion site is at a location where a delivery element (14), such as a cannula, needle, penetrates an individual's body. Preferably, one end of the delivery element is attached to a delivery device (10) and the other end is inserted through an individual's skin (16) terminating in an individual's subcutaneous tissue. The delivery device is attached to the surface of the individual's skin. In preferred embodiments of the present invention, the detection syste m includes a chemical positioned near the infusion site the reacts with preservatives in the leaking fluid to generate a highgly visible, brightly colored, chemical complex. In alternative embodiments, mechanical, electro-optical, electrochemical, electrical or oth er chemical systems may be used to detect the presence of fluid that is leaking near the infusion site.
Description
TITLE
Infusion Site Leak Detection System and Method of Using the Same FIELD OF THE INVENTION
This invention relates to infusion site leak detection systems and, in particular embodiments, to leak detection systems that detect when fluid is leaking under a delivery device, such as an infusion pump or an infusion set, near an infusion site.
BACKGROUND OF THE INVENTION
Continuous subcutaneous infusion of medications is becoming increasingly important. Typically, an individual uses a small pager size programmable pump to deliver a medication through a flexible plastic tube to an infusion set. The infusion set delivers medication to an individual's subcutaneous tissue through the use of either a rigid needle that is left in the tissue or through a flexible cannula that remains in the tissue after being inserted via a removable needle. The most common infused fluid is insulin. Currently, more than 70,000 individuals in the U.S., and about 30,000 more individuals worldwide, use subcutaneous infusion of insulin for the treatment of diabetes mellitus. However, other infused fluids include HIV
drugs, drugs to treat pulmonary hypertension, iron chelation drugs, pain medications, and 2 0 anti-cancer treatments.
Generally, one end of the cannula is attached to the infusion set and the other end is inserted through the individual's skin. An adhesive pad on a bottom of the infusion set adheres the infusion set to the individual's skin. Clear adhesive tape is often placed over the infusion set and in contact with the individual's skin to further 2 5 secure the infusion set and cannula.
A lealc near the infusion site can be one of the most serious problems that occurs while infusing a medication. Traditionally, leaks near the infusion site are caused by inadvertently pulling the cannula out of the body, or separating the cannula from an infusion set, or an inadequately sealed infusion set. A medication leaking 3 0 near the insertion site is often trapped by the adhesive and collects between the infusion set and the skin. And, even though the infusion set is typically made of clear plastic, it is hard for the individual to look at the infusion set and tell the difference between medication passing through the infusion set, and medication collecting under the infusion set. Also, most infused medications are delivered at a rate as low as a few micro liters per hour (~.1/Hr.). This delivery rate is so slow that individuals typically cannot discern between body moisture, such as sweat, and medication that has leaked onto the surface of their skin near the infusion site. Thus, hours may pass before a medication begins to seep out from under the adhesive pad . and chip down the individual's skin, drawing their attention to the leak. In the meantime, the individual may suffer significant consequences due to the lack of medication in their system. In the case of a diabetic individual infusing insulin, for example, the user could pass out due to hyperglycemia before realizing that insulin is not entering their body.
SUMMARY OF THE DISCLOSURE
According to an embodiment of the invention, a leak detection system is to detect the presence of a fluid to be delivered into an individual's body that has leaked near an infusion site. Embodiments of the present invention include a delivery device, a delivery element and at Ieast one chemical. The delivery device is adapted 2 o for attachment to the individual's body. The delivery element is configured to penetrate the individual's body at the infusion site and establish fluid communication between the delivery device and the individual's body, so that the fluid can travel from the delivery device into the individual's body. The at least one chemical is positioned near the infusion site and reacts with at least one component within the 2 5 fluid when the fluid is present near the infusion site.
In particular embodiments, a product of a chemical reaction, between the at least one chemical positioned near the infusion site and the at least one component within the fluid, is a colored complex. In specific embodiments, the at least one chemical positioned near the infusion site contains at least 4-amino-antipyrine and 3 0 potassium ferricyanide. liz other embodiments, the at least one chemical positioned near the infusion site contains at least 4-amino-antipyrine and potassium ferricyanide and horse radish peroxidase (HRP). Alternatively, the at least one chemical positioned near the infusion site contains at least ninhydrin. In additional embodiments, the at least one chemical positioned near the infusion site contains at least Coomassie Brilliant Blue.
Various methods may be used to position the at least one chemical near the infusion site. W some embodiments, the at least one chemical positioned near the infusion site is encapsulated in micro-spheres. In other embodiments, the at least one chemical positioned near the infusion site is a component of a gel. In further l 0 embodiments, the at least one chemical positioned near the infusion site is a component of an adhesive. And in still further embodiments, the at least one chemical positioned near the infusion site is associated with starch granules.
In particular embodiments, the delivery device includes a base, and the at least one chemical positioned near the infusion site is embedded in the base of the delivery device. Finally, in other embodiments, the at least one chemical positioned near the infusion site is deposited on the individual's body.
In particular embodiments, the delivery device is an infusion set. In other embodiments, the delivery device is an infusion pump.
According to another embodiment of the invention, a leaf detection system to 2 0 detect the presence of a fluid to be delivered into an individual's body that has leaked near an infusion site includes a delivery device, a delivery element, an adhesive tape, and at least one chemical. The delivery device is adapted for attachment to the individual's body. The delivery element is configured to penetrate the individual's body at the infusion site and establish fluid communication between the delivery 2 5 device and the individual's body, so that the fluid can travel from the delivery device into the individual's body. The adhesive tape is applied to a portion of the individual's body to hold the delivery device on the individual's body. The at least one chemical is associated with the adhesive tape and reacts with at least one component within the fluid when the fluid is present near the infusion site.
3 0 In particular embodiments, a product of a chemical reaction between the at least one chemical associated with the adhesive tape, and the at least one component within the fluid, is a colored complex. In additional embodiments, the at least one chemical associated with the adhesive tape is included with the adhesive on the adhesive tape.
According to a further embodiment of the invention, the leak detection system, to detect the presence of a fluid to be delivered into an individual's body that has leaked near an infusion site, includes a delivery device, a delivery element, at least one chemical, an optical receiver, and a light conducting element. The delivery device is adapted for attachment to the individual's body. The delivery element is configured to penetrate the individual's body at the infusion site and establish fluid communication between the delivery device acid the individual's body, so that the fluid cam travel from the delivery device into the individual's body. The at least one chemical is positioned near the infusion site, and reacts with at least one component within the fluid when the fluid is present near the infusion site. A product of a chemical reaction between the at least one chemical positioned near the infusion site and the at least one component within the fluid is a colored complex. The light conducting element guides light from a point near the infusion site to the optical receiver. The optical receiver detects a change in light when the colored complex is created by the chemical reaction and provides an output signal indicating that a leak 2 0 is detected. In particular embodiments, the light conducting element is at least one fiber optic cable. In alternative embodiments, the light conducting element is a flexible plastic tube filled with the fluid. Tn particular embodiments, the leak detection system includes an alarm system, controlled by the output signal, to notify the individual when a leak is detected. In more particular embodiments, the alarm 2 5 system produces an audible sound when a leak is detected, and in other embodiments, the alarm system activates a vibrator when a leak is detected.
According to yet another embodiment of the invention, a leak detection system to detect the presence of a fluid to be delivered into an individual's body that has leaked near an infusion site includes a delivery device, a delivery element, a 3 0 rosette, at least one electrical component, and a battery. The delivery device is adapted for attachment to the individual's body, and the delivery device includes a delivery device base. The delivery element is configured to penetrate the individual's body at the infusion site and establish fluid communication between the delivery device and an individual's body, so that the fluid can travel from the delivery device into the individual's body. The rosette is positioned on the delivery device base and substantially surrounds the delivery element. The at least one electrical component is coupled to the rosette and detects a change in at least one electrical characteristic associated with the rosette when a leak occurs. The battery supplies power to the at least one electrical component.
1 o In particular embodiments, the rosette is a closed circuit, and the impedance across the rosette decreases as fluid leaks near the infusion site. In alternative embodiments, the rosette is a closed circuit before a leak occurs, and at least portions of the rosette dissolve in the presence of the fluid. The impedance across the rosette increases as the at least portions of the rosette dissolve. In other particular l5 embodiments, the rosette is an open circuit, and the circuit is closed when fluid leaks near the infusion site. In alternative particular embodiments, one or more chemicals are positioned near the infusion site, and leaking fluid near the infusion site triggers an electrochemical reaction with the chemicals.
In particular embodiments, the at least one electrical component measures 2 0 voltage across the rosette. In other particular embodiments, the at least one electrical component measures impedance across the rosette. In still other embodiments, the at least one electrical component measures capacitance across the rosette.
In particular embodiments, the leak detection system includes an alarm 2 5 system, coupled to the battery and to the at least one electrical component, to notify and indicate when a leak is detected. The alarm system produces an audible somid when a leak is detected. In alternative embodiments, the alarm system activates a vibrator when a leak is detected.
According to an embodiment of the invention, a leak detection system to 3 0 detect the presence of a fluid to be delivered into an individual's body that has leaked near an intended delivery site includes a delivery attachment element, a delivery element, and at least one reactive element. The delivery attachment element is adapted for attachment to the delivery site and the delivery element. The delivery element is configured to penetrate the delivery site and establish fluid communication between the delivery attachment element and the individual's body, so that the fluid can travel from the delivery attachment element and into the individual's body. The at least one reactive element is positioned near the delivery site and coupled to at least one of, the delivery attachment element and the delivery element, so that when the fluid is present near the delivery site, the at least one I 0 reactive element reacts with at least one component within the fluid.
BRIEF DESCRIPTION OF THE DRAWINGS
A detailed description of embodiments of the invention will be made with reference to the accompanying drawings, wherein like numerals designate corresponding parts in the several figures.
Fig. 1 is a diagram showing an infusion set attached to a body, a flexible tube, and an infusion pump according to an embodiment of the present invention.
Fig. 2a is a cross-sectional side view of an infusion set attached to a body tissue.
2 0 Fig. 2b is a perspective bottom view of the infusion set of Fig. 2a with a pad partially cut away.
Fig. 3a is a side view of an infusion pump attached to a body tissue, with a partial cut away of the pump, showing a cross-sectional view of a delivery element penetrating the body tissue.
2 5 Fig. 3b is a side view of another infusion pump attached to a body tissue, showing a cross-sectional view of a delivery element penetrating the body tissue.
Fig. 4 is a diagram of a phenol molecule.
Fig. 5 is a diagram of a benzyl alcohol molecule.
Fig. 6 is a diagram of a 4-amino-antipyrine molecule.
3 0 Fig. 7 is a diagram of a potassium ferricyanide (K3Fe(CN)6 molecule.
Infusion Site Leak Detection System and Method of Using the Same FIELD OF THE INVENTION
This invention relates to infusion site leak detection systems and, in particular embodiments, to leak detection systems that detect when fluid is leaking under a delivery device, such as an infusion pump or an infusion set, near an infusion site.
BACKGROUND OF THE INVENTION
Continuous subcutaneous infusion of medications is becoming increasingly important. Typically, an individual uses a small pager size programmable pump to deliver a medication through a flexible plastic tube to an infusion set. The infusion set delivers medication to an individual's subcutaneous tissue through the use of either a rigid needle that is left in the tissue or through a flexible cannula that remains in the tissue after being inserted via a removable needle. The most common infused fluid is insulin. Currently, more than 70,000 individuals in the U.S., and about 30,000 more individuals worldwide, use subcutaneous infusion of insulin for the treatment of diabetes mellitus. However, other infused fluids include HIV
drugs, drugs to treat pulmonary hypertension, iron chelation drugs, pain medications, and 2 0 anti-cancer treatments.
Generally, one end of the cannula is attached to the infusion set and the other end is inserted through the individual's skin. An adhesive pad on a bottom of the infusion set adheres the infusion set to the individual's skin. Clear adhesive tape is often placed over the infusion set and in contact with the individual's skin to further 2 5 secure the infusion set and cannula.
A lealc near the infusion site can be one of the most serious problems that occurs while infusing a medication. Traditionally, leaks near the infusion site are caused by inadvertently pulling the cannula out of the body, or separating the cannula from an infusion set, or an inadequately sealed infusion set. A medication leaking 3 0 near the insertion site is often trapped by the adhesive and collects between the infusion set and the skin. And, even though the infusion set is typically made of clear plastic, it is hard for the individual to look at the infusion set and tell the difference between medication passing through the infusion set, and medication collecting under the infusion set. Also, most infused medications are delivered at a rate as low as a few micro liters per hour (~.1/Hr.). This delivery rate is so slow that individuals typically cannot discern between body moisture, such as sweat, and medication that has leaked onto the surface of their skin near the infusion site. Thus, hours may pass before a medication begins to seep out from under the adhesive pad . and chip down the individual's skin, drawing their attention to the leak. In the meantime, the individual may suffer significant consequences due to the lack of medication in their system. In the case of a diabetic individual infusing insulin, for example, the user could pass out due to hyperglycemia before realizing that insulin is not entering their body.
SUMMARY OF THE DISCLOSURE
According to an embodiment of the invention, a leak detection system is to detect the presence of a fluid to be delivered into an individual's body that has leaked near an infusion site. Embodiments of the present invention include a delivery device, a delivery element and at Ieast one chemical. The delivery device is adapted 2 o for attachment to the individual's body. The delivery element is configured to penetrate the individual's body at the infusion site and establish fluid communication between the delivery device and the individual's body, so that the fluid can travel from the delivery device into the individual's body. The at least one chemical is positioned near the infusion site and reacts with at least one component within the 2 5 fluid when the fluid is present near the infusion site.
In particular embodiments, a product of a chemical reaction, between the at least one chemical positioned near the infusion site and the at least one component within the fluid, is a colored complex. In specific embodiments, the at least one chemical positioned near the infusion site contains at least 4-amino-antipyrine and 3 0 potassium ferricyanide. liz other embodiments, the at least one chemical positioned near the infusion site contains at least 4-amino-antipyrine and potassium ferricyanide and horse radish peroxidase (HRP). Alternatively, the at least one chemical positioned near the infusion site contains at least ninhydrin. In additional embodiments, the at least one chemical positioned near the infusion site contains at least Coomassie Brilliant Blue.
Various methods may be used to position the at least one chemical near the infusion site. W some embodiments, the at least one chemical positioned near the infusion site is encapsulated in micro-spheres. In other embodiments, the at least one chemical positioned near the infusion site is a component of a gel. In further l 0 embodiments, the at least one chemical positioned near the infusion site is a component of an adhesive. And in still further embodiments, the at least one chemical positioned near the infusion site is associated with starch granules.
In particular embodiments, the delivery device includes a base, and the at least one chemical positioned near the infusion site is embedded in the base of the delivery device. Finally, in other embodiments, the at least one chemical positioned near the infusion site is deposited on the individual's body.
In particular embodiments, the delivery device is an infusion set. In other embodiments, the delivery device is an infusion pump.
According to another embodiment of the invention, a leaf detection system to 2 0 detect the presence of a fluid to be delivered into an individual's body that has leaked near an infusion site includes a delivery device, a delivery element, an adhesive tape, and at least one chemical. The delivery device is adapted for attachment to the individual's body. The delivery element is configured to penetrate the individual's body at the infusion site and establish fluid communication between the delivery 2 5 device and the individual's body, so that the fluid can travel from the delivery device into the individual's body. The adhesive tape is applied to a portion of the individual's body to hold the delivery device on the individual's body. The at least one chemical is associated with the adhesive tape and reacts with at least one component within the fluid when the fluid is present near the infusion site.
3 0 In particular embodiments, a product of a chemical reaction between the at least one chemical associated with the adhesive tape, and the at least one component within the fluid, is a colored complex. In additional embodiments, the at least one chemical associated with the adhesive tape is included with the adhesive on the adhesive tape.
According to a further embodiment of the invention, the leak detection system, to detect the presence of a fluid to be delivered into an individual's body that has leaked near an infusion site, includes a delivery device, a delivery element, at least one chemical, an optical receiver, and a light conducting element. The delivery device is adapted for attachment to the individual's body. The delivery element is configured to penetrate the individual's body at the infusion site and establish fluid communication between the delivery device acid the individual's body, so that the fluid cam travel from the delivery device into the individual's body. The at least one chemical is positioned near the infusion site, and reacts with at least one component within the fluid when the fluid is present near the infusion site. A product of a chemical reaction between the at least one chemical positioned near the infusion site and the at least one component within the fluid is a colored complex. The light conducting element guides light from a point near the infusion site to the optical receiver. The optical receiver detects a change in light when the colored complex is created by the chemical reaction and provides an output signal indicating that a leak 2 0 is detected. In particular embodiments, the light conducting element is at least one fiber optic cable. In alternative embodiments, the light conducting element is a flexible plastic tube filled with the fluid. Tn particular embodiments, the leak detection system includes an alarm system, controlled by the output signal, to notify the individual when a leak is detected. In more particular embodiments, the alarm 2 5 system produces an audible sound when a leak is detected, and in other embodiments, the alarm system activates a vibrator when a leak is detected.
According to yet another embodiment of the invention, a leak detection system to detect the presence of a fluid to be delivered into an individual's body that has leaked near an infusion site includes a delivery device, a delivery element, a 3 0 rosette, at least one electrical component, and a battery. The delivery device is adapted for attachment to the individual's body, and the delivery device includes a delivery device base. The delivery element is configured to penetrate the individual's body at the infusion site and establish fluid communication between the delivery device and an individual's body, so that the fluid can travel from the delivery device into the individual's body. The rosette is positioned on the delivery device base and substantially surrounds the delivery element. The at least one electrical component is coupled to the rosette and detects a change in at least one electrical characteristic associated with the rosette when a leak occurs. The battery supplies power to the at least one electrical component.
1 o In particular embodiments, the rosette is a closed circuit, and the impedance across the rosette decreases as fluid leaks near the infusion site. In alternative embodiments, the rosette is a closed circuit before a leak occurs, and at least portions of the rosette dissolve in the presence of the fluid. The impedance across the rosette increases as the at least portions of the rosette dissolve. In other particular l5 embodiments, the rosette is an open circuit, and the circuit is closed when fluid leaks near the infusion site. In alternative particular embodiments, one or more chemicals are positioned near the infusion site, and leaking fluid near the infusion site triggers an electrochemical reaction with the chemicals.
In particular embodiments, the at least one electrical component measures 2 0 voltage across the rosette. In other particular embodiments, the at least one electrical component measures impedance across the rosette. In still other embodiments, the at least one electrical component measures capacitance across the rosette.
In particular embodiments, the leak detection system includes an alarm 2 5 system, coupled to the battery and to the at least one electrical component, to notify and indicate when a leak is detected. The alarm system produces an audible somid when a leak is detected. In alternative embodiments, the alarm system activates a vibrator when a leak is detected.
According to an embodiment of the invention, a leak detection system to 3 0 detect the presence of a fluid to be delivered into an individual's body that has leaked near an intended delivery site includes a delivery attachment element, a delivery element, and at least one reactive element. The delivery attachment element is adapted for attachment to the delivery site and the delivery element. The delivery element is configured to penetrate the delivery site and establish fluid communication between the delivery attachment element and the individual's body, so that the fluid can travel from the delivery attachment element and into the individual's body. The at least one reactive element is positioned near the delivery site and coupled to at least one of, the delivery attachment element and the delivery element, so that when the fluid is present near the delivery site, the at least one I 0 reactive element reacts with at least one component within the fluid.
BRIEF DESCRIPTION OF THE DRAWINGS
A detailed description of embodiments of the invention will be made with reference to the accompanying drawings, wherein like numerals designate corresponding parts in the several figures.
Fig. 1 is a diagram showing an infusion set attached to a body, a flexible tube, and an infusion pump according to an embodiment of the present invention.
Fig. 2a is a cross-sectional side view of an infusion set attached to a body tissue.
2 0 Fig. 2b is a perspective bottom view of the infusion set of Fig. 2a with a pad partially cut away.
Fig. 3a is a side view of an infusion pump attached to a body tissue, with a partial cut away of the pump, showing a cross-sectional view of a delivery element penetrating the body tissue.
2 5 Fig. 3b is a side view of another infusion pump attached to a body tissue, showing a cross-sectional view of a delivery element penetrating the body tissue.
Fig. 4 is a diagram of a phenol molecule.
Fig. 5 is a diagram of a benzyl alcohol molecule.
Fig. 6 is a diagram of a 4-amino-antipyrine molecule.
3 0 Fig. 7 is a diagram of a potassium ferricyanide (K3Fe(CN)6 molecule.
Fig. 8 is a diagram of a bright blue chemical complex.
Fig. 9 is a cross-sectional side view of the infusion set of Fig. 2a, with a fiber optic cable.
Fig. l0a is a top view diagram of an uninterrupted rosette substantially surrounding an infusion site.
Fig, l Ob is a top view diagram of a discontinuous rosette substantially surrounding an infusion site.
Fig. l Oc is a top view diagram of an uninterrupted rosette with a dissolvable portion substantially surrounding an infusion site.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
As shown in the drawings for purposes of illustration, the invention is embodied in an infusion Ieak detection system designed to indicate the presence of a fluid to be delivered into an individual's body that has leaked near an infusion site.
The infusion site is at a location where a delivery element, such as a cannula, needle, or the like, penetrates an individual's body. Preferably, one end of the delivery element is attached to a delivery device and the other end is inserted through an individual's skin terminating in an individual's subcutaneous tissue. The delivery element establishes fluid communication between the delivery device and the 2 0 individual's subcutaneous tissue. In alternative embodiments, the delivery element may terminate in an other tissue such as, muscle, organ, inter-peritoneal, intra-peritoneal, or the lilce. The delivery device is attached to the surface of the individual's skin. Tn preferred embodiments of the present invention, the detection system includes a chemical positioned near the infusion site that reacts with 2 5 preservatives in the leaking fluid to generate a highly visible, brightly colored, chemical complex. In alternative embodiments, mechanical, electro-optical, electrochemical, electrical or other chemical systems may be used to detect the presence of fluid that is leaking near the infusion site. Preferred embodiments are for use with human beings; however, alternative embodiments may be used with animals 3 0 or fluid flow applications where detection of small amounts of leaking fluid is WO 41/681b3 PCT/US01/07~81 important.
An infusion pump regulates the flow of fluid into an individual's subcutaneous tissue. In preferred embodiments, shown in Fig. 1, the fluid flows from an infusion pump 10, through a flexible tube 12, and into the delivery device such as, an infusion set I4, or the Iike, that is adhered to the individual's skin 16.
Infusion sets 14 that may be used as a delivery device are described in, but not limited to, U.S. Patents; 4,723,947; 4,755,173; 5,176,662; and 5,584,813; and disclosed inU.S.Patentl3o. 6,056,718, which issued on rsay 2, 2000.
The infusion pump 10 may be of the type described in U.S. Patents 4,562,751; 4,685,903; 5,080,653; 5,505,709; and.5,097,122., Alternatively, other infusion pumps may be used for delivery of fluid through an infusion set 14 to au individual's body. As shown in Fig. 2a, the delivery element, such as a cannula I 8 or the like, directs the fluid from a cavity 54 inside the infusion set 14, through the individual's skin 16, and into the individual's subcutaneous tissue 22. The characteristics of cannula 18, such as the length, inner 2 0 and outer diameter, end configurations, and materials may vary depending on the tissue type that the cannula is inserted into, the volume and type of fluid being infused, the configuration of the delivery device and other parameters. In alternative embodiments the delivery device is an infusion pump 24 adhered directly to the individual's skin 16. hz a particular embodiment, shown in Fig. 3a, the infusion 2 5 pump 24 has a cannula 18' as the delivery element, to deliver fluid directly from the infusion pump 24 through the individual's skin I6 to the subcutaneous tissue 22.
Fig. 3b shows another particular embodiment illustrating infusion pump 24'with a needle 26 for the delivery element. The infusion pump 24 may be of the type described in U.S. Patents; 4,902,278; 5,785,688; 5,814,020; 5,848,991; and 3 0 5,858,001; or other small disposable pumps for delivery of fluid through a delivery _g_ element to an individual's body, lil particular embodiments, other fluid conducting delivery elements are used such as, capillaries, conduits, needles, lumens, or the like.
The most connnon cause of leaking fluid is due to the delivery element inadvertently slipping out of an individual's body. This generally occurs if the delivery device (an infusion set 14 or an infusion pump 24) connected to the delivery element, lifts away from the individual's skin 16. Consequently, in preferred embodiments, the delivery device includes one or more pads 28 to attach the delivery device to the individual's skin. The pads 28 include an adhesive, and the pad may be made of an adhesive, foam, glue, tape, a substrate coated with adhesive, or the like.
1 o The pads 28 are generally arranged around the infusion site 30 and serve to hold the delivery device on the individual's slcin 16. One of the one or more pads 28 may be located on a delivery device base 32. Pads 28 are various sizes and shapes to accommodate the different footprints that different delivery devices have on the individual's skin 16. A pad 28 for an infusion set 14 is shown in Figs. 2a and 2b.
Pads 28' and 28", shown in Figs. 3a and 3b respectively, are attached to the delivery device bases 32' and 32" respectively for particular embodiments of infusion pumps 24 and 24' respectively. In other embodiments, the delivery device is held to the individual's skin 16 with a tape 34. In still other embodiments, both the adhesive of the pad 28 and tape 34 are used to secure the delivery device to the individual's skin 2 0 16.
There may be other causes of leaking fluid near the infusion site 30. For Example, the cannula 18 may separate from the delivery device or an inadequately sealed delivery device could leak fluid. In these cases, fluid leaking near the infusion site 30 may be trapped by the surrounding pads 28 and collect between the delivery 2 5 device and the individual's skin 16. Consequently, the fluid is substantially not infused into the individual's body.
In preferred embodiments the infused fluid is insulin. However, many other fluids may be administered through infusion such as, but not limited to, HIV
drugs, drugs to treat pulmonary hypertension, iron chelation drugs, pain medications, anti-3 0 cancer treatments, vitamins, hormones, or the like.
_g_ Most fluids designed for parenteral administration (and/or infusion) contain a preservative. The most commonly used preservatives are based either on a phenol system 32 or a benzyl alcohol system 34. Examples of these systems are shown in Figs. 4 and 5 respectively. Thus, one approach to detecting a leak is to trigger a chemical reaction that is observable by an individual when any of these preservatives are present in a fluid leaked near the infusion site 30.
In preferred embodiments, a clear gel containing 4-amino-antipyrine 36, shown in Figs. 6, and potassium ferricyanide 38 (I~3 Fe (C1~6), shown in Fig.
Fig. 9 is a cross-sectional side view of the infusion set of Fig. 2a, with a fiber optic cable.
Fig. l0a is a top view diagram of an uninterrupted rosette substantially surrounding an infusion site.
Fig, l Ob is a top view diagram of a discontinuous rosette substantially surrounding an infusion site.
Fig. l Oc is a top view diagram of an uninterrupted rosette with a dissolvable portion substantially surrounding an infusion site.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
As shown in the drawings for purposes of illustration, the invention is embodied in an infusion Ieak detection system designed to indicate the presence of a fluid to be delivered into an individual's body that has leaked near an infusion site.
The infusion site is at a location where a delivery element, such as a cannula, needle, or the like, penetrates an individual's body. Preferably, one end of the delivery element is attached to a delivery device and the other end is inserted through an individual's skin terminating in an individual's subcutaneous tissue. The delivery element establishes fluid communication between the delivery device and the 2 0 individual's subcutaneous tissue. In alternative embodiments, the delivery element may terminate in an other tissue such as, muscle, organ, inter-peritoneal, intra-peritoneal, or the lilce. The delivery device is attached to the surface of the individual's skin. Tn preferred embodiments of the present invention, the detection system includes a chemical positioned near the infusion site that reacts with 2 5 preservatives in the leaking fluid to generate a highly visible, brightly colored, chemical complex. In alternative embodiments, mechanical, electro-optical, electrochemical, electrical or other chemical systems may be used to detect the presence of fluid that is leaking near the infusion site. Preferred embodiments are for use with human beings; however, alternative embodiments may be used with animals 3 0 or fluid flow applications where detection of small amounts of leaking fluid is WO 41/681b3 PCT/US01/07~81 important.
An infusion pump regulates the flow of fluid into an individual's subcutaneous tissue. In preferred embodiments, shown in Fig. 1, the fluid flows from an infusion pump 10, through a flexible tube 12, and into the delivery device such as, an infusion set I4, or the Iike, that is adhered to the individual's skin 16.
Infusion sets 14 that may be used as a delivery device are described in, but not limited to, U.S. Patents; 4,723,947; 4,755,173; 5,176,662; and 5,584,813; and disclosed inU.S.Patentl3o. 6,056,718, which issued on rsay 2, 2000.
The infusion pump 10 may be of the type described in U.S. Patents 4,562,751; 4,685,903; 5,080,653; 5,505,709; and.5,097,122., Alternatively, other infusion pumps may be used for delivery of fluid through an infusion set 14 to au individual's body. As shown in Fig. 2a, the delivery element, such as a cannula I 8 or the like, directs the fluid from a cavity 54 inside the infusion set 14, through the individual's skin 16, and into the individual's subcutaneous tissue 22. The characteristics of cannula 18, such as the length, inner 2 0 and outer diameter, end configurations, and materials may vary depending on the tissue type that the cannula is inserted into, the volume and type of fluid being infused, the configuration of the delivery device and other parameters. In alternative embodiments the delivery device is an infusion pump 24 adhered directly to the individual's skin 16. hz a particular embodiment, shown in Fig. 3a, the infusion 2 5 pump 24 has a cannula 18' as the delivery element, to deliver fluid directly from the infusion pump 24 through the individual's skin I6 to the subcutaneous tissue 22.
Fig. 3b shows another particular embodiment illustrating infusion pump 24'with a needle 26 for the delivery element. The infusion pump 24 may be of the type described in U.S. Patents; 4,902,278; 5,785,688; 5,814,020; 5,848,991; and 3 0 5,858,001; or other small disposable pumps for delivery of fluid through a delivery _g_ element to an individual's body, lil particular embodiments, other fluid conducting delivery elements are used such as, capillaries, conduits, needles, lumens, or the like.
The most connnon cause of leaking fluid is due to the delivery element inadvertently slipping out of an individual's body. This generally occurs if the delivery device (an infusion set 14 or an infusion pump 24) connected to the delivery element, lifts away from the individual's skin 16. Consequently, in preferred embodiments, the delivery device includes one or more pads 28 to attach the delivery device to the individual's skin. The pads 28 include an adhesive, and the pad may be made of an adhesive, foam, glue, tape, a substrate coated with adhesive, or the like.
1 o The pads 28 are generally arranged around the infusion site 30 and serve to hold the delivery device on the individual's slcin 16. One of the one or more pads 28 may be located on a delivery device base 32. Pads 28 are various sizes and shapes to accommodate the different footprints that different delivery devices have on the individual's skin 16. A pad 28 for an infusion set 14 is shown in Figs. 2a and 2b.
Pads 28' and 28", shown in Figs. 3a and 3b respectively, are attached to the delivery device bases 32' and 32" respectively for particular embodiments of infusion pumps 24 and 24' respectively. In other embodiments, the delivery device is held to the individual's skin 16 with a tape 34. In still other embodiments, both the adhesive of the pad 28 and tape 34 are used to secure the delivery device to the individual's skin 2 0 16.
There may be other causes of leaking fluid near the infusion site 30. For Example, the cannula 18 may separate from the delivery device or an inadequately sealed delivery device could leak fluid. In these cases, fluid leaking near the infusion site 30 may be trapped by the surrounding pads 28 and collect between the delivery 2 5 device and the individual's skin 16. Consequently, the fluid is substantially not infused into the individual's body.
In preferred embodiments the infused fluid is insulin. However, many other fluids may be administered through infusion such as, but not limited to, HIV
drugs, drugs to treat pulmonary hypertension, iron chelation drugs, pain medications, anti-3 0 cancer treatments, vitamins, hormones, or the like.
_g_ Most fluids designed for parenteral administration (and/or infusion) contain a preservative. The most commonly used preservatives are based either on a phenol system 32 or a benzyl alcohol system 34. Examples of these systems are shown in Figs. 4 and 5 respectively. Thus, one approach to detecting a leak is to trigger a chemical reaction that is observable by an individual when any of these preservatives are present in a fluid leaked near the infusion site 30.
In preferred embodiments, a clear gel containing 4-amino-antipyrine 36, shown in Figs. 6, and potassium ferricyanide 38 (I~3 Fe (C1~6), shown in Fig.
7, is deposited on the delivery device base 32, within the pad 28, or with an adhesive. Tn particular embodiments, the delivery device is a clear plastic infusion set 14 with a delivery device base 32 as shown in Figs 2a and 2b. In other embodiments, such as the one shown in Fig. 3a for example, the delivery device is an infusion pump with clear plastic parts incorporated in the infusion pmnp (not shown), as necessary, for the individual to see through the infusion pump 24 and observe the gel near the infusion site 30. In alternative embodiments, the delivery device may include other clear (optically transparent) materials, such as glass, creams, crystal, laminates, or the like for the individual to see through the delivery device and observe the gel near the infusion site 30.
In other alternative embodiments, the chemicals are deposited on a pad 28 2 o made of hydrogel, cloth, fibrous material, porous material, or other materials that wick away fluid, so that the leaking fluid from the infusion site 30 is drawn to the edges of the pad 28. Then the color change from the reaction can be seen around the edges of the delivery device. The pad 28 may extend beyond the perimeter of the delivery device so that the edges of the pad 28 are easily observable to the user. In 2 5 this embodiment, portions of the delivery device or the entire delivery device may be opaque since the color change does not have to be observed through the device.
When a leak occurs, the preservative in the parenteral fluid reacts with the 4-amino-antipyrine 36 and potassium ferricyanide 38 in the gel. The resulting product is a bright blue colored complex 40. Thus, the chemicals, seen through the delivery 3 0 device or around the edges of the device, change from clear to bright blue, serving as a visual indicator to the individual that a leak has occurred. A drawing of the structure of the resulting bright blue colored complex 40 is shown in Fig. 8.
The time required to detect the leak is typically one to two hours. However, the time required fox detection may be short as 5 minutes or as long as 8 hours due to the concentrations of the reactants, 4-amino-antipyrine 36 and potassium ferricyanide 38, the concentration of the preservative in the fluid, the leak rate of the fluid, the rate at which the leaking fluid spreads and comes in contact with the reactants, the method used to deposit the chemicals near the infusion site 30, the temperature near the infusion site 30, and the presence of contaminants such as body fluids. In alternative embodiments, the clear gel may be some other color, such as white, cream, off white, or the like, or a contrasting color to make the color change noticeable. In other embodiments, the colored product is a different color, such as red, yellow, orange, pink, green, purple, or the like.
In alternative embodiments, an enzymatic system is used to amplify the chemical color change signal. An enzyme, such as horse radish peroxidase (HRP), is added to the gel containing 4-aminoantipyrine 36 and potassium ferricyanide 38.
When a leak occurs, water in the leaking fluid dissolves the HRP. The HR.P
then acts as a catalyst to, in essence, create an enzymatic amplification of the signal.
Again, a deep blue colored complex 40 is formed due to the phenol 32 or benzyl 2 0 alcohol 34 preservatives in the fluid reacting with 4-aminoantipyrine 36 and potassium ferncyanide 38. The advantage of the HRP system is that only very small amounts of the leaked fluid need to be present to be detected. For example, with HRP present in the gel, a fluid lealcing at a rate of only 8 microliters per hour can be detected in approximately 15 to 20 minutes. Where as without HRP, the same leak 2 5 might take 1 to 2 hours to be detectable. In alternative embodiments, the time required to detect a leak can range from less than 20 sec. to over 4 hours depending on the concentration of HRP present in the gel, the concentration of the reactants 4-arninoantipyrine 36 and potassium ferncyanide 38, the method used to deposit the chemicals near the infusion site 30, the rate that the leaking fluid spreads and comes in contact with the reactants, the temperature near the infusion site 30, and the concentration of contaminates such as body fluids near the infusion site 30.
In further alternative embodiments, the 4-aminoantipyrine 36 and potassium ferricyanide 38 are encapsulated in micro-spheres and blended into the adhesive used to hold the delivery device to the individual's skin 16. In particular embodiments, the micro-spheres dissolve in the presence of an ingredient contained in the infused fluid, such as water, alcohol, or the like, which then sets the reactants free to react with the preservative in the fluid as described above. Additional embodiments include HRP
encapsulated in micro-spheres along with 4-aminoantipyrine 36 and potassium l0 ferncyanide 38. In other embodiments, different methods are employed to position the 4-aminoantipyrine 36, potassium ferricyanide 38 and perhaps HRP near the infusion site 30. These methods include mixing them directly into an adhesive, applying them with starch granules, depositing them in pockets formed in a delivery device base 32 and/or pads) 28, encapsulating them and mixing them with a gel, embedding them into the delivery device base 32, spreading them on the individual's skin 16, or the like. Still further embodiments apply the 4-aminoantipyrine 36 and potassium ferricyanide 38, perhaps along with HRP, to the adhesive tape 34 applied to the delivery device as an overdressing and/or an underdressing. For instance, a clear adhesive tape 34 prepared with the reactants and/or catalyst can be applied around a 2 0 delivery device that is attached to the individual's skin I6. In another example, the adhesive tape 34 with reactants is placed on the individual's slcin 16 under the delivery device. In both instances, when fluid leaks near the infusion site 30, the bright blue colored complex 40, product of the reaction, is visible through the adhesive tape 34.
In other embodiments, where the fluid to be delivered into an individual's 2 5 body includes a protein, such as an insulin formulation, other reactants may be located near the infusion site 30 to produce a color change that signifies a leak. In particular embodiments, either ninhydrin or Coomassie Brilliant Blue reacts with the protein in the fluid resulting in a brightly colored product. A potential drawback to both of these reactants, is that it will irreversibly stain the individual's skin 16 until 3 o the individual's skin 16 is exfoliated. Thus, other non-staining compounds might be WO 01/68163 PCTlUS01/07981 used.
While chemical reactions are effective at displaying a visual signal (a color change) when fluid is leaking, the individual must visually inspect around the delivery device or at the infiusion site 30 to see the visual signal. Thus, alternative methods of Ieak detection. utilize an audible or tactile notification of a leak in addition to, or instead of, a visual only signal.
In particular embodiments, optical or electrical detection methods provide a signal to electronics contained within an infusion pump housing 44. When a leak is detected, the electronics activate an alarm. Specific embodiments include an audible alarm that the individual can hear when a leak is detected. Alternative embodiments have other alarm mechanisms such as a vibrator, flashing lights or LEDs, an LCD
message displaying the cause for alarm, a small scintillating electric shock to the individual, a heating element, or the like. In other alternative embodiments, the alarm generates at least one notification signal such as by telemeixy, radio freduency, Z5 optical, infra-red, ultrasonic, laser, telephone, pager, or the like.
In 2 0 particular embodiments, an alarm notification is stored in a memory device such as an on-board memory chip, a computer memory, a palm pilot, computer disks, compact disks, a telephone message, a pager, or the like. In. other embodiments, the alarm notifies a person other than the individual using the infusion pump (10 or 24), i.e. a doctor, a nurse, a parent, a spouse, a friend, a relative, a work mate, or the Iike.
2 5 Some embodiments of the current invention use an electro-optical detection system in combination with anyof the chemical reactions that result in a colored chemical product like those previously described. An optical receiver receives light from near the infusion site 30. When chemical reactants produce a colored product, the optical receiver detects a change in the light indicating a fluid has leaked. The 3 0 optical receiver provides an output signal to the electronics. In particular embodiments, a miniature optical transmitter and receiver are located near the infusion site 30. The exterior surface of either the transmitter, or the receiver, or both, are coated with reactants that will produce a colored complex 40 in the presence of the leaking fluid. When a leak triggers the color change, the optical signal between the optical transmitter and optical receiver is altered. The optical signal is carned to the electronics by a fiber optical cable 42, or is converted to an electrical signal and carried to the electronics by electrical wire, or the like. Fig. 9 illustrates a fiber optic cable 42 that carnes a light signal from the infusion site 30 through the infusion set 14'. Chemically activated color changes are detected by the optical receiver through the fiber optic cable 42. In alternative embodiments, more than one fiber optic cable 42 may be used to carry light from more than one location near the infusion site 30 to the optical receiver. In another embodiment, the optical receiver and an optical transmitter are both located inside the infusion pump housing 44. A first fiber optic cable runs from the optical transmitter to a point near the infusion site 30, and a second fiber optic cable runs from the optical receiver to a point near the infusion site 30. The ends of the fiber optic cables near the infusion site 30 are positioned with respect to each other so that light emitted by the optical transmitter is detected by the optical receiver. A gap exists between the ends of the fiber optic cables near the infusion site 30. Gel, or adhesive, or another Garner media 2 0 containing the reactants, is placed in the gap between the ends of the fiber optic cables. When a leaking fluid triggers a reaction producing a chemical color change, a change in the light signal is detected by the optical receiver.
Still other embodiments take advantage of the light conducting characteristics of the flexible tube 12 when it is filled with the fluid. An optical receiver, located in 2 5 the infusion pump housing 44, is positioned, with respect to a first end of the flexible tube 12, to receive light carried through the flexible tube 12 from an infusion set. In particular embodiments, a second end of the flexible tube 12 is positioned with respect to the cannula 18 of the infusion set, such that light entering an exposed cannula 18 travels through the flexible tube 12 to the optical receiver. While the 3 0 cannula 18 is in the individual's body, the optical receiver detects virtually no light since very little light passes through the body tissue surrounding the cannula 18.
When the cannula 18 is pulled out, light enters the cannula 18 and is detected by the optical receiver. The optical receiver responds particularly to light wavelengths that are substantially absorbed or blocked by tissues near the surface of the body.
In other embodiments, the second end of tlae flexible tube 12 is positioned to receive light from an area near the infusion site 30. When a leak causes a chemical reaction resulting in a color change near the infusion site 30, the light traveling through the flexible tube changes color and the optical receiver detects a change in light indicating that a lealc has occurred.
Z 0 In embodiments that do not use a flexible tube 12 between the delivery device and the infusion pump 10, for example, when the infusion pump is attached directly to the individual's skin 16 near the infusion site 30, the optical receiver is located within the infusion pump housing and is positioned with respect to the cannula 18 (or needle 26) such that light coming from the cannula 18 (or needle) is detected by the optical receiver. If sufficient light is detected by the optical receiver, it is an indication that the cannula (or needle 26) is not in the individual's body and a leak has occurred.
Other leak detection methods are based on electrical measurements. An infusion pump battery is an available source for the electrical power required to 2 0 operate an electrically based detection apparatus. Electroucs contained within the infusion pump housing 44 evaluate the signals from the electrically based detection apparatus. In preferred embodiments, conductive leads such as, wires, conductors, traces, or the like, are enclosed within the wall of the flexible tube 12 that carries the fluid from the infusion pump 10 to an infusion set 14. In particular embodiments, 2 5 the conductive leads run through the flexible tube walls in a helical path. In other embodiments the conductive leads run straight down the flexible tube 12.
Alternatively, in other embodiments, the conductive leads are external to the flexible tube 12. Additionally, embodiments that include an infusion pump 24 adhered to the individual's skin 16 may have conductive leads contained within the infusion pump 3 0 housing 44 if needed. Further alternative embodiments may include external conductive leads that are printed, silk screened, stamped, ink jetted, adhered, or the like onto the flexible tube 12.
In preferred embodiments, a rosette, which is a pattern of one or more conducting elements, is embedded in the delivery device base, or applied to the surface of the delivery device base, to substantially surround the infusion site 30.
Conducting elements may be wires, sputtered carbon, plastics doped with conductive fillers, epoxies doped with conductive fillers, or the like. Particular embodiments employ an active electronic signal to detect changes in impedance across the rosette.
For instance, a voltage is supplied across the rosette by running conductive leads from the pump battery to different points on the rosette, such as opposite or adjacent end points. Then the impedance is measured across the rosette. When fluid leaks onto the rosette, the impedance changes and the electronics measure the change in impedance to detect a leak. In preferred embodiments, an uninterrupted rosette 46 is used, such as an example sown in Fig. 10a; when a fluid leaks near the infusion site 30, it shorts out portions of the rosette 46 providing additional or shorter conductive paths across portions of the rosette 46, and the total impedance across the rosette 46 decreases. The reduction in impedance across the rosette 46 is detected by the electronics which indicates a fluid leak. Many other uninterrupted rosette patterns will work as long as fluid leaking near the infusion site 30 will short out a sufficient 2 o portion of the rosette for a measurable change in impedance to be detectable.
Uninterrupted rosettes have a continuous conductive path so that the voltage drop across the rosette is measurable, and is not zero. Thus, a test voltage may be used to confirm that there are no disconnects or opens in the circuit leading from the electronics to the rosette and back. In preferred embodiments, the impedance of the 2 5 fluid to be detected, and the impedance of the conductive leads leading from the electroiucs to the rosette are low compared to the impedance across the rosette.
Thus, the high impedance of the rosette decreases rapidly as relatively highly conductive fluid spreads across the rosette. hi alternative embodiments, the impedance of the fluid and or the leads is not low compared to the impedance of the 3 o rosette, and therefore the electronics are tuned to detect small shifts in the change of the impedance across the rosette.
In other embodiments, portions of the rosette are designed to dissolve away in the presence of the fluid being infused. An example of a particular embodiment of an uninterrupted rosette 48 with a dissolvable portion 50 near the infusion site 30 is shown in Fig. l Oc. When a leak occurs, at least a part of the dissolvable portion 50 of the rosette 48 dissolves, and the impedance across the rosette 48 increases. In fact, if enough of the rosette 48 dissolves, the rosette 48 may become an open circuit.
This increased impedance is detected by the infusion pump electronics. Many different continuous rosette patterns may be used so long as the dissolvable portion of the rosette substantially surrounds the infusion site 30. This embodiment is functions even if the fluid is not conductive.
In alternative embodiments, the rosette is discontinuous. The conductive path is interrupted and fluid lealeed near the infusion site 30 is required to close the open circuit. Although many designs of discontinuous rosettes may be used, one embodiment is shown in Fig. lOb. The normal voltage reading across the discontinuous rosette 52 is zero. Fluid leaked near the infusion site 30 shorts portions of the rosette 52 and closes the circuit. The conductive leads, the rosette 52, and the fluid near the infusion site 30 must have sufficiently high conductivity compared to an open circuit for the fluid to be detected. In other embodiments, a change in 2 0 capacitance is measured to detect the presence of a fluid.
In another embodiment, compounds are added into the adhesive so that the conductive properties of the adhesive change in the presence of the infused fluid.
However, it is preferred that the presence of salt, water or sweat alone does not change impedance of the adhesive or if the impedance does change due to salt, water 2 5 or sweat, that it changes in a predetermined or predictable maimer. A
rosette, on the delivery device base, substantially surrounds the infusion site 30, and is in direct contact with the adhesive. But the rosette is insulated from the individual's skin 16 by the adhesive. Therefore, the rosette does not undergo a change in impedance due to natural body fluids on the surface of the individual's skin 16. However, when a 3 0 fluid leak occurs, the impedance of the adhesive changes, and therefore, the impedance measured across the rosette changes, which is then detected by the electronics.
In alternative embodiments, the rosette may be in contact with a material that wicks fluid away from near the infusion site 30 and spreads the fluid quickly across the rosette for an accelerated response. In further embodiments, a wicking material may be used with the chemical reactions described above, to accelerate the reaction or make the resulting product of the reaction more visible.
In other embodiments, electrical power is not supplied to the rosette.
Instead, leaking fluid reacts with one or more chemical compounds in contact with a rosette 1 o near the infusion site 30. The electrochemical reaction generates an electrical charge, and the voltage measured across a discontinuous rosette increases from zero to a detectable voltage level indicating that the fluid has leaked. Ii1 particular embodiments, two unconnected electrodes 56 and 58, of rosette 52 shown in Fig.
l Ob, are made of different metals and coated with different chemicals. The electrodes 56 and 58 are separated from the skin by a material such as a hydrogel or other material that is dry before a leak occurs, yet after a leak the wetted hydrogel or other material conducts electricity. Either of the electrodes, 56 for example, is made of platinum and is coated with HRP and 4-aminoantipyrine 36. The other electrode, 58 for example, is made of silver that is chloridized. When the electrodes 56 and 58 2 0 are dry, there is no voltage across the electrodes 56 and 58. Once a leak occurs, the phenol 32 or other preservative within the leaking fluid begins to react with the HRP
and 4-aminoaaztipyrine 36. The voltage across the electrodes 56 and 58 will be about 650 mV or less. In one embodiment, the voltage is applied across an LED (not shown) included as part of the infusion set 14, causing the LED to flash when a leak 2 5 is detected. In alternative embodiments, the resulting voltage generated across the electrodes 56 and 58 is applied to other notification devices included as part of the infixsion set 14 such as a piezo electric sound emanating device, another sound emanating device, a piezo electric vibration device, another vibration device, a LED
that lights up or changes color when the voltage is supplied, a RF
transmitting device 3 0 that signals the infusion pump 10, or the like. In other alternative embodiments, the voltage across the electrodes 56 and 58 is carned by a wire to the infusion pump 10 and the infusion pump 10 triggers an alarm. In still other embodiments, the voltage is applied to the individual's skin 16 to notify the individual with a minor electric shock. In other particular embodiments, other concentrations or other reactants may be used to generate a greater or lesser voltage differential across the electrodes, 56 and 58. W other embodiments, electrode 58 is made of platinum and is coated with HRP and 4-aminoantipyrine 36, and the other electrode 56 is made of silver that is chloridized. In additional embodiments, other discontinuous rosettes are used.
In further embodiments, a change in impedance is detected if a delivery device, such as an infusion set 14 or an infusion pump 24, lifts off of the individual's skin 16 and the delivery element, such as a cannula 18 or a needle 26, becomes dislodged from the subcutaneous tissue 22. A change in impedance indicates that the delivery element is no longer in the individual's body, and therefore the fluid is leaking. In particular embodiments, a pair of electrodes are mounted on the delivery device base to measure impedance across the individual's skin 16. When one or both electrodes lose contact with the individual's skin 16, the increased impedance between the electrodes is sensed by the infusion pump electronics indicating a fluid leak. Alternatively, a change in capacitance between the electrodes may be measured to detect when the delivery device lifts off of the individual's skin 16. The relative 2 0 capacitance increases when one or more electrodes lose touch with the individual's skin 16.
Other embodiments use electrodes located on an exterior of the cannula to detect whether the delivery element is inserted in the individual's body. Body fluid in the subcutaneous tissue 22 is substantially more conductive than infused fluids.
2 5 When a cannula is pulled from the body, the measured impedance across the electrodes on the cannula increases indicating that a leak is detected.
Particular embodiments include a non-removable needle centered inside a cannula as one electrode and a metal sheath on the external surface of the cannula as the other electrode. In an alternative embodiments, the electrodes are conductive strips on the 3 o external surface of the cannula. Other embodiments include a first electrode attached to the delivery element, such as a cannula or a needle, and a second electrode touching the surface of the individual's skin 16, such as on the delivery device base attached to the individual's skin 16. This method is easier to use if the delivery element inserted in the individual's body is conductive, such as a steel needle, a cannula with a conductive coating, a cannula with conductors on the exterior surface, or the like. Again, impedance increases when the delivery element is pulled out of the individual's body. Alternatively, capacitance is measured instead of impedance, since capacitance increases when the delivery element is pulled out of the individual's body.
In alternative embodiments, the lealcing fluid triggers an exothermic chemical reaction. The individual feels their skin near the infusion site 30 become warm when a leak occurs. Visual inspection of the infusion site 30 is replaced by a tactile temperature change. Tn other embodiments, both the color change method and an exothermic reaction are used.
While the description above refers to particular embodiments of the present invention, it will be understood that many modifications may be made without departing from the spirit thereof. The accompanying claims are intended to cover such modifications as would fall within the true scope and spirit of the present invention.
2 0 The presently disclosed embodiments are therefore to be considered in all respects as illustrative and not restrictive, the scope of the invention being indicated by the appended claims, rather than the foregoing description, and all changes wluch come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein.
In other alternative embodiments, the chemicals are deposited on a pad 28 2 o made of hydrogel, cloth, fibrous material, porous material, or other materials that wick away fluid, so that the leaking fluid from the infusion site 30 is drawn to the edges of the pad 28. Then the color change from the reaction can be seen around the edges of the delivery device. The pad 28 may extend beyond the perimeter of the delivery device so that the edges of the pad 28 are easily observable to the user. In 2 5 this embodiment, portions of the delivery device or the entire delivery device may be opaque since the color change does not have to be observed through the device.
When a leak occurs, the preservative in the parenteral fluid reacts with the 4-amino-antipyrine 36 and potassium ferricyanide 38 in the gel. The resulting product is a bright blue colored complex 40. Thus, the chemicals, seen through the delivery 3 0 device or around the edges of the device, change from clear to bright blue, serving as a visual indicator to the individual that a leak has occurred. A drawing of the structure of the resulting bright blue colored complex 40 is shown in Fig. 8.
The time required to detect the leak is typically one to two hours. However, the time required fox detection may be short as 5 minutes or as long as 8 hours due to the concentrations of the reactants, 4-amino-antipyrine 36 and potassium ferricyanide 38, the concentration of the preservative in the fluid, the leak rate of the fluid, the rate at which the leaking fluid spreads and comes in contact with the reactants, the method used to deposit the chemicals near the infusion site 30, the temperature near the infusion site 30, and the presence of contaminants such as body fluids. In alternative embodiments, the clear gel may be some other color, such as white, cream, off white, or the like, or a contrasting color to make the color change noticeable. In other embodiments, the colored product is a different color, such as red, yellow, orange, pink, green, purple, or the like.
In alternative embodiments, an enzymatic system is used to amplify the chemical color change signal. An enzyme, such as horse radish peroxidase (HRP), is added to the gel containing 4-aminoantipyrine 36 and potassium ferricyanide 38.
When a leak occurs, water in the leaking fluid dissolves the HRP. The HR.P
then acts as a catalyst to, in essence, create an enzymatic amplification of the signal.
Again, a deep blue colored complex 40 is formed due to the phenol 32 or benzyl 2 0 alcohol 34 preservatives in the fluid reacting with 4-aminoantipyrine 36 and potassium ferncyanide 38. The advantage of the HRP system is that only very small amounts of the leaked fluid need to be present to be detected. For example, with HRP present in the gel, a fluid lealcing at a rate of only 8 microliters per hour can be detected in approximately 15 to 20 minutes. Where as without HRP, the same leak 2 5 might take 1 to 2 hours to be detectable. In alternative embodiments, the time required to detect a leak can range from less than 20 sec. to over 4 hours depending on the concentration of HRP present in the gel, the concentration of the reactants 4-arninoantipyrine 36 and potassium ferncyanide 38, the method used to deposit the chemicals near the infusion site 30, the rate that the leaking fluid spreads and comes in contact with the reactants, the temperature near the infusion site 30, and the concentration of contaminates such as body fluids near the infusion site 30.
In further alternative embodiments, the 4-aminoantipyrine 36 and potassium ferricyanide 38 are encapsulated in micro-spheres and blended into the adhesive used to hold the delivery device to the individual's skin 16. In particular embodiments, the micro-spheres dissolve in the presence of an ingredient contained in the infused fluid, such as water, alcohol, or the like, which then sets the reactants free to react with the preservative in the fluid as described above. Additional embodiments include HRP
encapsulated in micro-spheres along with 4-aminoantipyrine 36 and potassium l0 ferncyanide 38. In other embodiments, different methods are employed to position the 4-aminoantipyrine 36, potassium ferricyanide 38 and perhaps HRP near the infusion site 30. These methods include mixing them directly into an adhesive, applying them with starch granules, depositing them in pockets formed in a delivery device base 32 and/or pads) 28, encapsulating them and mixing them with a gel, embedding them into the delivery device base 32, spreading them on the individual's skin 16, or the like. Still further embodiments apply the 4-aminoantipyrine 36 and potassium ferricyanide 38, perhaps along with HRP, to the adhesive tape 34 applied to the delivery device as an overdressing and/or an underdressing. For instance, a clear adhesive tape 34 prepared with the reactants and/or catalyst can be applied around a 2 0 delivery device that is attached to the individual's skin I6. In another example, the adhesive tape 34 with reactants is placed on the individual's slcin 16 under the delivery device. In both instances, when fluid leaks near the infusion site 30, the bright blue colored complex 40, product of the reaction, is visible through the adhesive tape 34.
In other embodiments, where the fluid to be delivered into an individual's 2 5 body includes a protein, such as an insulin formulation, other reactants may be located near the infusion site 30 to produce a color change that signifies a leak. In particular embodiments, either ninhydrin or Coomassie Brilliant Blue reacts with the protein in the fluid resulting in a brightly colored product. A potential drawback to both of these reactants, is that it will irreversibly stain the individual's skin 16 until 3 o the individual's skin 16 is exfoliated. Thus, other non-staining compounds might be WO 01/68163 PCTlUS01/07981 used.
While chemical reactions are effective at displaying a visual signal (a color change) when fluid is leaking, the individual must visually inspect around the delivery device or at the infiusion site 30 to see the visual signal. Thus, alternative methods of Ieak detection. utilize an audible or tactile notification of a leak in addition to, or instead of, a visual only signal.
In particular embodiments, optical or electrical detection methods provide a signal to electronics contained within an infusion pump housing 44. When a leak is detected, the electronics activate an alarm. Specific embodiments include an audible alarm that the individual can hear when a leak is detected. Alternative embodiments have other alarm mechanisms such as a vibrator, flashing lights or LEDs, an LCD
message displaying the cause for alarm, a small scintillating electric shock to the individual, a heating element, or the like. In other alternative embodiments, the alarm generates at least one notification signal such as by telemeixy, radio freduency, Z5 optical, infra-red, ultrasonic, laser, telephone, pager, or the like.
In 2 0 particular embodiments, an alarm notification is stored in a memory device such as an on-board memory chip, a computer memory, a palm pilot, computer disks, compact disks, a telephone message, a pager, or the like. In. other embodiments, the alarm notifies a person other than the individual using the infusion pump (10 or 24), i.e. a doctor, a nurse, a parent, a spouse, a friend, a relative, a work mate, or the Iike.
2 5 Some embodiments of the current invention use an electro-optical detection system in combination with anyof the chemical reactions that result in a colored chemical product like those previously described. An optical receiver receives light from near the infusion site 30. When chemical reactants produce a colored product, the optical receiver detects a change in the light indicating a fluid has leaked. The 3 0 optical receiver provides an output signal to the electronics. In particular embodiments, a miniature optical transmitter and receiver are located near the infusion site 30. The exterior surface of either the transmitter, or the receiver, or both, are coated with reactants that will produce a colored complex 40 in the presence of the leaking fluid. When a leak triggers the color change, the optical signal between the optical transmitter and optical receiver is altered. The optical signal is carned to the electronics by a fiber optical cable 42, or is converted to an electrical signal and carried to the electronics by electrical wire, or the like. Fig. 9 illustrates a fiber optic cable 42 that carnes a light signal from the infusion site 30 through the infusion set 14'. Chemically activated color changes are detected by the optical receiver through the fiber optic cable 42. In alternative embodiments, more than one fiber optic cable 42 may be used to carry light from more than one location near the infusion site 30 to the optical receiver. In another embodiment, the optical receiver and an optical transmitter are both located inside the infusion pump housing 44. A first fiber optic cable runs from the optical transmitter to a point near the infusion site 30, and a second fiber optic cable runs from the optical receiver to a point near the infusion site 30. The ends of the fiber optic cables near the infusion site 30 are positioned with respect to each other so that light emitted by the optical transmitter is detected by the optical receiver. A gap exists between the ends of the fiber optic cables near the infusion site 30. Gel, or adhesive, or another Garner media 2 0 containing the reactants, is placed in the gap between the ends of the fiber optic cables. When a leaking fluid triggers a reaction producing a chemical color change, a change in the light signal is detected by the optical receiver.
Still other embodiments take advantage of the light conducting characteristics of the flexible tube 12 when it is filled with the fluid. An optical receiver, located in 2 5 the infusion pump housing 44, is positioned, with respect to a first end of the flexible tube 12, to receive light carried through the flexible tube 12 from an infusion set. In particular embodiments, a second end of the flexible tube 12 is positioned with respect to the cannula 18 of the infusion set, such that light entering an exposed cannula 18 travels through the flexible tube 12 to the optical receiver. While the 3 0 cannula 18 is in the individual's body, the optical receiver detects virtually no light since very little light passes through the body tissue surrounding the cannula 18.
When the cannula 18 is pulled out, light enters the cannula 18 and is detected by the optical receiver. The optical receiver responds particularly to light wavelengths that are substantially absorbed or blocked by tissues near the surface of the body.
In other embodiments, the second end of tlae flexible tube 12 is positioned to receive light from an area near the infusion site 30. When a leak causes a chemical reaction resulting in a color change near the infusion site 30, the light traveling through the flexible tube changes color and the optical receiver detects a change in light indicating that a lealc has occurred.
Z 0 In embodiments that do not use a flexible tube 12 between the delivery device and the infusion pump 10, for example, when the infusion pump is attached directly to the individual's skin 16 near the infusion site 30, the optical receiver is located within the infusion pump housing and is positioned with respect to the cannula 18 (or needle 26) such that light coming from the cannula 18 (or needle) is detected by the optical receiver. If sufficient light is detected by the optical receiver, it is an indication that the cannula (or needle 26) is not in the individual's body and a leak has occurred.
Other leak detection methods are based on electrical measurements. An infusion pump battery is an available source for the electrical power required to 2 0 operate an electrically based detection apparatus. Electroucs contained within the infusion pump housing 44 evaluate the signals from the electrically based detection apparatus. In preferred embodiments, conductive leads such as, wires, conductors, traces, or the like, are enclosed within the wall of the flexible tube 12 that carries the fluid from the infusion pump 10 to an infusion set 14. In particular embodiments, 2 5 the conductive leads run through the flexible tube walls in a helical path. In other embodiments the conductive leads run straight down the flexible tube 12.
Alternatively, in other embodiments, the conductive leads are external to the flexible tube 12. Additionally, embodiments that include an infusion pump 24 adhered to the individual's skin 16 may have conductive leads contained within the infusion pump 3 0 housing 44 if needed. Further alternative embodiments may include external conductive leads that are printed, silk screened, stamped, ink jetted, adhered, or the like onto the flexible tube 12.
In preferred embodiments, a rosette, which is a pattern of one or more conducting elements, is embedded in the delivery device base, or applied to the surface of the delivery device base, to substantially surround the infusion site 30.
Conducting elements may be wires, sputtered carbon, plastics doped with conductive fillers, epoxies doped with conductive fillers, or the like. Particular embodiments employ an active electronic signal to detect changes in impedance across the rosette.
For instance, a voltage is supplied across the rosette by running conductive leads from the pump battery to different points on the rosette, such as opposite or adjacent end points. Then the impedance is measured across the rosette. When fluid leaks onto the rosette, the impedance changes and the electronics measure the change in impedance to detect a leak. In preferred embodiments, an uninterrupted rosette 46 is used, such as an example sown in Fig. 10a; when a fluid leaks near the infusion site 30, it shorts out portions of the rosette 46 providing additional or shorter conductive paths across portions of the rosette 46, and the total impedance across the rosette 46 decreases. The reduction in impedance across the rosette 46 is detected by the electronics which indicates a fluid leak. Many other uninterrupted rosette patterns will work as long as fluid leaking near the infusion site 30 will short out a sufficient 2 o portion of the rosette for a measurable change in impedance to be detectable.
Uninterrupted rosettes have a continuous conductive path so that the voltage drop across the rosette is measurable, and is not zero. Thus, a test voltage may be used to confirm that there are no disconnects or opens in the circuit leading from the electronics to the rosette and back. In preferred embodiments, the impedance of the 2 5 fluid to be detected, and the impedance of the conductive leads leading from the electroiucs to the rosette are low compared to the impedance across the rosette.
Thus, the high impedance of the rosette decreases rapidly as relatively highly conductive fluid spreads across the rosette. hi alternative embodiments, the impedance of the fluid and or the leads is not low compared to the impedance of the 3 o rosette, and therefore the electronics are tuned to detect small shifts in the change of the impedance across the rosette.
In other embodiments, portions of the rosette are designed to dissolve away in the presence of the fluid being infused. An example of a particular embodiment of an uninterrupted rosette 48 with a dissolvable portion 50 near the infusion site 30 is shown in Fig. l Oc. When a leak occurs, at least a part of the dissolvable portion 50 of the rosette 48 dissolves, and the impedance across the rosette 48 increases. In fact, if enough of the rosette 48 dissolves, the rosette 48 may become an open circuit.
This increased impedance is detected by the infusion pump electronics. Many different continuous rosette patterns may be used so long as the dissolvable portion of the rosette substantially surrounds the infusion site 30. This embodiment is functions even if the fluid is not conductive.
In alternative embodiments, the rosette is discontinuous. The conductive path is interrupted and fluid lealeed near the infusion site 30 is required to close the open circuit. Although many designs of discontinuous rosettes may be used, one embodiment is shown in Fig. lOb. The normal voltage reading across the discontinuous rosette 52 is zero. Fluid leaked near the infusion site 30 shorts portions of the rosette 52 and closes the circuit. The conductive leads, the rosette 52, and the fluid near the infusion site 30 must have sufficiently high conductivity compared to an open circuit for the fluid to be detected. In other embodiments, a change in 2 0 capacitance is measured to detect the presence of a fluid.
In another embodiment, compounds are added into the adhesive so that the conductive properties of the adhesive change in the presence of the infused fluid.
However, it is preferred that the presence of salt, water or sweat alone does not change impedance of the adhesive or if the impedance does change due to salt, water 2 5 or sweat, that it changes in a predetermined or predictable maimer. A
rosette, on the delivery device base, substantially surrounds the infusion site 30, and is in direct contact with the adhesive. But the rosette is insulated from the individual's skin 16 by the adhesive. Therefore, the rosette does not undergo a change in impedance due to natural body fluids on the surface of the individual's skin 16. However, when a 3 0 fluid leak occurs, the impedance of the adhesive changes, and therefore, the impedance measured across the rosette changes, which is then detected by the electronics.
In alternative embodiments, the rosette may be in contact with a material that wicks fluid away from near the infusion site 30 and spreads the fluid quickly across the rosette for an accelerated response. In further embodiments, a wicking material may be used with the chemical reactions described above, to accelerate the reaction or make the resulting product of the reaction more visible.
In other embodiments, electrical power is not supplied to the rosette.
Instead, leaking fluid reacts with one or more chemical compounds in contact with a rosette 1 o near the infusion site 30. The electrochemical reaction generates an electrical charge, and the voltage measured across a discontinuous rosette increases from zero to a detectable voltage level indicating that the fluid has leaked. Ii1 particular embodiments, two unconnected electrodes 56 and 58, of rosette 52 shown in Fig.
l Ob, are made of different metals and coated with different chemicals. The electrodes 56 and 58 are separated from the skin by a material such as a hydrogel or other material that is dry before a leak occurs, yet after a leak the wetted hydrogel or other material conducts electricity. Either of the electrodes, 56 for example, is made of platinum and is coated with HRP and 4-aminoantipyrine 36. The other electrode, 58 for example, is made of silver that is chloridized. When the electrodes 56 and 58 2 0 are dry, there is no voltage across the electrodes 56 and 58. Once a leak occurs, the phenol 32 or other preservative within the leaking fluid begins to react with the HRP
and 4-aminoaaztipyrine 36. The voltage across the electrodes 56 and 58 will be about 650 mV or less. In one embodiment, the voltage is applied across an LED (not shown) included as part of the infusion set 14, causing the LED to flash when a leak 2 5 is detected. In alternative embodiments, the resulting voltage generated across the electrodes 56 and 58 is applied to other notification devices included as part of the infixsion set 14 such as a piezo electric sound emanating device, another sound emanating device, a piezo electric vibration device, another vibration device, a LED
that lights up or changes color when the voltage is supplied, a RF
transmitting device 3 0 that signals the infusion pump 10, or the like. In other alternative embodiments, the voltage across the electrodes 56 and 58 is carned by a wire to the infusion pump 10 and the infusion pump 10 triggers an alarm. In still other embodiments, the voltage is applied to the individual's skin 16 to notify the individual with a minor electric shock. In other particular embodiments, other concentrations or other reactants may be used to generate a greater or lesser voltage differential across the electrodes, 56 and 58. W other embodiments, electrode 58 is made of platinum and is coated with HRP and 4-aminoantipyrine 36, and the other electrode 56 is made of silver that is chloridized. In additional embodiments, other discontinuous rosettes are used.
In further embodiments, a change in impedance is detected if a delivery device, such as an infusion set 14 or an infusion pump 24, lifts off of the individual's skin 16 and the delivery element, such as a cannula 18 or a needle 26, becomes dislodged from the subcutaneous tissue 22. A change in impedance indicates that the delivery element is no longer in the individual's body, and therefore the fluid is leaking. In particular embodiments, a pair of electrodes are mounted on the delivery device base to measure impedance across the individual's skin 16. When one or both electrodes lose contact with the individual's skin 16, the increased impedance between the electrodes is sensed by the infusion pump electronics indicating a fluid leak. Alternatively, a change in capacitance between the electrodes may be measured to detect when the delivery device lifts off of the individual's skin 16. The relative 2 0 capacitance increases when one or more electrodes lose touch with the individual's skin 16.
Other embodiments use electrodes located on an exterior of the cannula to detect whether the delivery element is inserted in the individual's body. Body fluid in the subcutaneous tissue 22 is substantially more conductive than infused fluids.
2 5 When a cannula is pulled from the body, the measured impedance across the electrodes on the cannula increases indicating that a leak is detected.
Particular embodiments include a non-removable needle centered inside a cannula as one electrode and a metal sheath on the external surface of the cannula as the other electrode. In an alternative embodiments, the electrodes are conductive strips on the 3 o external surface of the cannula. Other embodiments include a first electrode attached to the delivery element, such as a cannula or a needle, and a second electrode touching the surface of the individual's skin 16, such as on the delivery device base attached to the individual's skin 16. This method is easier to use if the delivery element inserted in the individual's body is conductive, such as a steel needle, a cannula with a conductive coating, a cannula with conductors on the exterior surface, or the like. Again, impedance increases when the delivery element is pulled out of the individual's body. Alternatively, capacitance is measured instead of impedance, since capacitance increases when the delivery element is pulled out of the individual's body.
In alternative embodiments, the lealcing fluid triggers an exothermic chemical reaction. The individual feels their skin near the infusion site 30 become warm when a leak occurs. Visual inspection of the infusion site 30 is replaced by a tactile temperature change. Tn other embodiments, both the color change method and an exothermic reaction are used.
While the description above refers to particular embodiments of the present invention, it will be understood that many modifications may be made without departing from the spirit thereof. The accompanying claims are intended to cover such modifications as would fall within the true scope and spirit of the present invention.
2 0 The presently disclosed embodiments are therefore to be considered in all respects as illustrative and not restrictive, the scope of the invention being indicated by the appended claims, rather than the foregoing description, and all changes wluch come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein.
Claims (24)
1. ~A leak detection system to detect the presence of a fluid to be delivered into an individual's body that has leaked near an infu-sion site, the leak detection system comprising:
a delivery device adapted fox attachment to the individual's body;
a delivery element configured to penetrate the individual's body at the infusion site and establish fluid communication be-tween the delivery device and the individual's body, so that the fluid can travel from the delivery device into the individual's body; and at least one chemical, positioned near the infusion site, that reacts with at least one component within the fluid when the fluid is present near the infusion site.
a delivery device adapted fox attachment to the individual's body;
a delivery element configured to penetrate the individual's body at the infusion site and establish fluid communication be-tween the delivery device and the individual's body, so that the fluid can travel from the delivery device into the individual's body; and at least one chemical, positioned near the infusion site, that reacts with at least one component within the fluid when the fluid is present near the infusion site.
2.~A leak detection system according to claim 1, wherein a product of a chemical reaction, between the at least one chemical posi-tinned near the infusion site and the at least one component within the fluid, is a colored complex.
3. ~A leak detection system according to claim 1, wherein the at least one chemical positioned near the infusion site contains at least 4-aminoantipyrine and potassium ferricyanide.
4. ~A leak detection system according to claim 1, wherein the at least one chemical positioned near the infusion site contains at least 4-aminoantipyrine and potassium ferricyanide and horse radish peroxidase (HRP).
5. ~A leak detection system according to claim 1, wherein the at least one chemical positioned near the infusion site contains at least ninhydrin.
6. A leak detection system according to claim 1, wherein the at least one chemical positioned near the infusion site contains at least Coomassie Brilliant Blue.
7. A leak detection system according to claim 1, wherein the at least one chemical positioned near the infusion site is encapsulated in micro-spheres.
8. A leak detection system according to claim 1, wherein the at least one chemical positioned near the infusion site is a component of a~
gel.~
gel.~
9. A leak detection system according to claim 1, wherein the at least one chemical positioned near the infusion site is a component of an adhesive.
10. A leak detection system according to claim 1, wherein the at least one chemical positioned near the infusion site is associated with starch granules.
11. A leak detection system according to claim 1, wherein the deliv-ery device includes a base, and wherein the at least one chemical positioned near the infusion site is embedded in the base of the delivery device.
12. A leak detection system according to claim 1, wherein the at least one chemical positioned near the infusion site is deposited on the individual's body.
13. A leak detection system according to claim 1, wherein the deliv-ery device is an infusion set.
-3-~
-3-~
14. A leak detection system according to claim 1, wherein the deliv-ery device is an infusion pump.
15. A leak detection system to detect the presence of a fluid to be delivered into an individual's body that has leaked near an infu-sion site, the leak detection system comprising:
a delivery device adapted for attachment to the individual's body;
a delivery element configured to penetrate the individual's body at the infusion site and establish fluid communication be-tween the delivery device and the individual's body, so that the fluid can travel from the delivery device into the individual's body;
an adhesive tape that is applied to a portion of the individ-ual's body to hold the delivery device on the individual's body;
and at least one chemical associated with the adhesive tape that reacts with at least one component within the fluid when the fluid is present near the infusion site.
a delivery device adapted for attachment to the individual's body;
a delivery element configured to penetrate the individual's body at the infusion site and establish fluid communication be-tween the delivery device and the individual's body, so that the fluid can travel from the delivery device into the individual's body;
an adhesive tape that is applied to a portion of the individ-ual's body to hold the delivery device on the individual's body;
and at least one chemical associated with the adhesive tape that reacts with at least one component within the fluid when the fluid is present near the infusion site.
16. A leak detection system according to claim 15, wherein a product of a chemical reaction between the at least one chemical associ-ated with the adhesive tape and the at least one component within the fluid is a colored complex.
17. A leak detection system according to claim 15, wherein the at least one chemical associated with the adhesive tape is included with the adhesive on the adhesive tape.
-4-~
-4-~
18. A leak detection system to detect the presence of a fluid to be delivered into an individual's body that has leaked near an infu-sion site, the leak detection system comprising:
a delivery device adapted for attachment to the individual's body;
a delivery element configured to penetrate the individual's body at the infusion site and establish fluid communication be-tween the delivery device and the individual's body, so that the fluid can travel from the delivery device into the individual's body;
at least one chemical positioned near the infusion site that reacts with at least one component within the fluid when the fluid is present near the infusion site;
a product of a chemical reaction between the at least one chemical positioned near the infusion site and the at least one component within the fluid is a colored complex;
an optical receiver that detects a change in light when the colored complex is created by the chemical reaction and provides an output signal indicating that a leak is detected; and a light conducting element that guides light from a point near the infusion site to the optical receiver.
a delivery device adapted for attachment to the individual's body;
a delivery element configured to penetrate the individual's body at the infusion site and establish fluid communication be-tween the delivery device and the individual's body, so that the fluid can travel from the delivery device into the individual's body;
at least one chemical positioned near the infusion site that reacts with at least one component within the fluid when the fluid is present near the infusion site;
a product of a chemical reaction between the at least one chemical positioned near the infusion site and the at least one component within the fluid is a colored complex;
an optical receiver that detects a change in light when the colored complex is created by the chemical reaction and provides an output signal indicating that a leak is detected; and a light conducting element that guides light from a point near the infusion site to the optical receiver.
19. A leak detection system according to claim 18, wherein the light conducting element is at least one fiber optic cable.
20. A leak detection system according to claim 18, wherein the light conducting element is a flexible tube filled with the fluid.
21. A leak detection system according to claim 18, wherein the leak detection system includes an alarm system, controlled by the output signal, to notify the individual when the leak is detected.
22. A leak detection system according to claim 21, wherein the alarm system produces an audible sound when the leak is detected.
23. A leak detection system according to claim 21, wherein the alarm system activates a vibrator when the leak is detected.
24. A leak detection system to detect the presence of a fluid to be delivered into an individual's body that has leaked near an in-tended delivery site, the leak detection system comprising:
a delivery attachment element adapted for attachment to the delivery site;
a delivery element configured to penetrate the delivery site and establish fluid communication between the delivery attach-ment element and the individual's body, so that the fluid can travel from the delivery attachment element and into the individ-ual's body; and at least one reactive element positioned near the delivery site and coupled to at least one of the delivery attachment element and the delivery element so that when the fluid is present near the delivery site, the at least one reactive element reacts with at least one component within the fluid.
a delivery attachment element adapted for attachment to the delivery site;
a delivery element configured to penetrate the delivery site and establish fluid communication between the delivery attach-ment element and the individual's body, so that the fluid can travel from the delivery attachment element and into the individ-ual's body; and at least one reactive element positioned near the delivery site and coupled to at least one of the delivery attachment element and the delivery element so that when the fluid is present near the delivery site, the at least one reactive element reacts with at least one component within the fluid.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/524,021 US6461329B1 (en) | 2000-03-13 | 2000-03-13 | Infusion site leak detection system and method of using the same |
| US09/524,021 | 2000-03-13 | ||
| PCT/US2001/007481 WO2001068163A2 (en) | 2000-03-13 | 2001-03-09 | Infusion site leak detection system and method of using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2400689A1 CA2400689A1 (en) | 2001-09-20 |
| CA2400689C true CA2400689C (en) | 2006-02-21 |
Family
ID=24087421
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002400689A Expired - Fee Related CA2400689C (en) | 2000-03-13 | 2001-03-09 | Infusion site leak detection system and method of using the same |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US6461329B1 (en) |
| EP (1) | EP1263488B1 (en) |
| JP (1) | JP3713239B2 (en) |
| AT (1) | ATE347915T1 (en) |
| AU (1) | AU2001245538A1 (en) |
| CA (1) | CA2400689C (en) |
| DE (1) | DE60125149T2 (en) |
| WO (1) | WO2001068163A2 (en) |
Families Citing this family (190)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05186504A (en) * | 1990-07-16 | 1993-07-27 | Shin Etsu Chem Co Ltd | Polymer scale deposition inhibitor and method of preventing polymer scale deposition |
| EP1368080A4 (en) | 2001-03-04 | 2007-08-15 | Sterling Medivations Inc | Infusion hub assembly and fluid line disconnect system |
| US8034026B2 (en) | 2001-05-18 | 2011-10-11 | Deka Products Limited Partnership | Infusion pump assembly |
| MXPA03010576A (en) | 2001-05-18 | 2004-05-27 | Deka Products Lp | Infusion set for a fluid pump. |
| US7147615B2 (en) † | 2001-06-22 | 2006-12-12 | Baxter International Inc. | Needle dislodgement detection |
| US6689100B2 (en) * | 2001-10-05 | 2004-02-10 | Becton, Dickinson And Company | Microdevice and method of delivering or withdrawing a substance through the skin of an animal |
| US20030128125A1 (en) | 2002-01-04 | 2003-07-10 | Burbank Jeffrey H. | Method and apparatus for machine error detection by combining multiple sensor inputs |
| US9717840B2 (en) | 2002-01-04 | 2017-08-01 | Nxstage Medical, Inc. | Method and apparatus for machine error detection by combining multiple sensor inputs |
| US10155082B2 (en) | 2002-04-10 | 2018-12-18 | Baxter International Inc. | Enhanced signal detection for access disconnection systems |
| US20040254513A1 (en) | 2002-04-10 | 2004-12-16 | Sherwin Shang | Conductive polymer materials and applications thereof including monitoring and providing effective therapy |
| US7022098B2 (en) | 2002-04-10 | 2006-04-04 | Baxter International Inc. | Access disconnection systems and methods |
| US7052480B2 (en) | 2002-04-10 | 2006-05-30 | Baxter International Inc. | Access disconnection systems and methods |
| US7338465B2 (en) * | 2002-07-02 | 2008-03-04 | Patton Medical Devices, Lp | Infusion device and method thereof |
| US20050075670A1 (en) * | 2002-10-07 | 2005-04-07 | Henrik Bengtsson | Signal device with electro-muscle stimulation feature |
| US7399401B2 (en) * | 2002-10-09 | 2008-07-15 | Abbott Diabetes Care, Inc. | Methods for use in assessing a flow condition of a fluid |
| US7993108B2 (en) | 2002-10-09 | 2011-08-09 | Abbott Diabetes Care Inc. | Variable volume, shape memory actuated insulin dispensing pump |
| US7727181B2 (en) | 2002-10-09 | 2010-06-01 | Abbott Diabetes Care Inc. | Fluid delivery device with autocalibration |
| EP2386758A1 (en) | 2002-10-09 | 2011-11-16 | Abbott Diabetes Care Inc. | A method of pumping a predetermined dose of a medical fluid |
| US6902544B2 (en) * | 2003-01-22 | 2005-06-07 | Codman & Shurtleff, Inc. | Troubleshooting accelerator system for implantable drug delivery pumps |
| ES2737835T3 (en) | 2003-04-23 | 2020-01-16 | Valeritas Inc | Hydraulically driven pump for long-term medication administration |
| US7679407B2 (en) | 2003-04-28 | 2010-03-16 | Abbott Diabetes Care Inc. | Method and apparatus for providing peak detection circuitry for data communication systems |
| EP1475113A1 (en) * | 2003-05-08 | 2004-11-10 | Novo Nordisk A/S | External needle inserter |
| ATE392223T1 (en) * | 2003-05-08 | 2008-05-15 | Novo Nordisk As | INTERNAL NEEDLE INTRODUCER |
| JP4509100B2 (en) * | 2003-05-08 | 2010-07-21 | ノボ・ノルデイスク・エー／エス | Infusion device attachable to skin with removable needle insertion actuation |
| EP1502613A1 (en) * | 2003-08-01 | 2005-02-02 | Novo Nordisk A/S | Needle device with retraction means |
| US6979306B2 (en) * | 2003-08-13 | 2005-12-27 | Moll Family Trust | Method and device for monitoring loss of body fluid and dislodgment of medical instrument from body |
| KR20060099520A (en) * | 2003-10-21 | 2006-09-19 | 노보 노르디스크 에이/에스 | Medical skin mountable device |
| US8029454B2 (en) | 2003-11-05 | 2011-10-04 | Baxter International Inc. | High convection home hemodialysis/hemofiltration and sorbent system |
| US7520867B2 (en) * | 2003-11-10 | 2009-04-21 | Medtronic Minimed, Inc. | Subcutaneous infusion set |
| US7494481B2 (en) * | 2004-12-03 | 2009-02-24 | Medtronic Minimed, Inc. | Multi-position infusion set device and process |
| US7309326B2 (en) | 2003-11-18 | 2007-12-18 | Icu Medical, Inc. | Infusion set |
| CN100586495C (en) * | 2004-03-30 | 2010-02-03 | 诺和诺德公司 | Actuator system comprising lever mechanism |
| SE0401632D0 (en) * | 2004-06-24 | 2004-06-24 | Innovation Team Ab | Means and ways to detect blood leakage from wounds |
| WO2006014425A1 (en) | 2004-07-02 | 2006-02-09 | Biovalve Technologies, Inc. | Methods and devices for delivering glp-1 and uses thereof |
| US20060020298A1 (en) * | 2004-07-20 | 2006-01-26 | Camilleri Michael L | Systems and methods for curbing appetite |
| US20090012472A1 (en) * | 2004-09-22 | 2009-01-08 | Novo Nordisk A/S | Medical Device with Cannula Inserter |
| CN101027095B (en) * | 2004-09-22 | 2010-09-29 | 诺和诺德公司 | Medical device with cannula inserter |
| US7454955B2 (en) * | 2004-10-29 | 2008-11-25 | Hewlett-Packard Development Company, L.P. | Leak detection structure |
| EP1824536B1 (en) * | 2004-12-06 | 2009-08-26 | Novo Nordisk A/S | Ventilated skin mountable device |
| EP1830699A2 (en) * | 2004-12-22 | 2007-09-12 | Novo Nordisk A/S | Sensor system and method for detecting problems with mounting of skin mountable medical devices |
| JP2008528086A (en) | 2005-01-24 | 2008-07-31 | ノボ・ノルデイスク・エー／エス | Medical device with protected puncture device |
| US7985199B2 (en) * | 2005-03-17 | 2011-07-26 | Unomedical A/S | Gateway system |
| EP1863559A4 (en) | 2005-03-21 | 2008-07-30 | Abbott Diabetes Care Inc | Method and system for providing integrated medication infusion and analyte monitoring system |
| US7905868B2 (en) | 2006-08-23 | 2011-03-15 | Medtronic Minimed, Inc. | Infusion medium delivery device and method with drive device for driving plunger in reservoir |
| US8277415B2 (en) | 2006-08-23 | 2012-10-02 | Medtronic Minimed, Inc. | Infusion medium delivery device and method with drive device for driving plunger in reservoir |
| US20060253085A1 (en) * | 2005-05-06 | 2006-11-09 | Medtronic Minimed, Inc. | Dual insertion set |
| US8512288B2 (en) * | 2006-08-23 | 2013-08-20 | Medtronic Minimed, Inc. | Infusion medium delivery device and method with drive device for driving plunger in reservoir |
| US7641649B2 (en) | 2005-05-06 | 2010-01-05 | Medtronic Minimed, Inc. | Reservoir support and method for infusion device |
| WO2006120253A2 (en) * | 2005-05-13 | 2006-11-16 | Novo Nordisk A/S | Medical device adapted to detect disengagement of a transcutaneous device |
| US7768408B2 (en) | 2005-05-17 | 2010-08-03 | Abbott Diabetes Care Inc. | Method and system for providing data management in data monitoring system |
| DK200500774A (en) * | 2005-05-27 | 2006-09-27 | Danish Care Technology | Method for detecting a leak in an extracorporeal blood system |
| US7620437B2 (en) | 2005-06-03 | 2009-11-17 | Abbott Diabetes Care Inc. | Method and apparatus for providing rechargeable power in data monitoring and management systems |
| US7951182B2 (en) * | 2005-07-14 | 2011-05-31 | Zoll Circulation, Inc. | System and method for leak detection in external cooling pad |
| AU2006297601A1 (en) | 2005-08-22 | 2007-04-12 | Patton Medical Devices, Lp | Fluid delivery devices, systems and methods |
| US20070051166A1 (en) * | 2005-09-02 | 2007-03-08 | Baker Kenneth R | Leak detection systems and methods |
| US7534226B2 (en) | 2005-09-26 | 2009-05-19 | M2 Group Holdings, Inc. | Dispensing fluid from an infusion pump system |
| US8551046B2 (en) | 2006-09-18 | 2013-10-08 | Asante Solutions, Inc. | Dispensing fluid from an infusion pump system |
| JP4640642B2 (en) * | 2005-10-12 | 2011-03-02 | ニプロ株式会社 | Needle extraction detector |
| US7583190B2 (en) | 2005-10-31 | 2009-09-01 | Abbott Diabetes Care Inc. | Method and apparatus for providing data communication in data monitoring and management systems |
| CN101389366B (en) | 2005-11-03 | 2012-12-26 | 巴顿医疗设备有限公司 | Fluid delivery devices and system |
| WO2007056504A1 (en) * | 2005-11-08 | 2007-05-18 | M2 Medical A/S | Infusion pump system |
| US7641612B1 (en) | 2006-01-17 | 2010-01-05 | Mccall Kenneth Shawn | Blood loss detection for hemodialysis system |
| US8344966B2 (en) | 2006-01-31 | 2013-01-01 | Abbott Diabetes Care Inc. | Method and system for providing a fault tolerant display unit in an electronic device |
| US8657788B2 (en) | 2006-02-07 | 2014-02-25 | Tecpharma Licensing Ag | Infusion set |
| US11364335B2 (en) | 2006-02-09 | 2022-06-21 | Deka Products Limited Partnership | Apparatus, system and method for fluid delivery |
| US11027058B2 (en) | 2006-02-09 | 2021-06-08 | Deka Products Limited Partnership | Infusion pump assembly |
| US10010669B2 (en) | 2006-02-09 | 2018-07-03 | Deka Products Limited Partnership | Systems and methods for fluid delivery |
| US11478623B2 (en) | 2006-02-09 | 2022-10-25 | Deka Products Limited Partnership | Infusion pump assembly |
| US11497846B2 (en) | 2006-02-09 | 2022-11-15 | Deka Products Limited Partnership | Patch-sized fluid delivery systems and methods |
| EP2335754B1 (en) | 2006-02-09 | 2013-12-18 | DEKA Products Limited Partnership | Patch-sized fluid delivery systems |
| CN101401314B (en) * | 2006-03-13 | 2013-04-24 | 诺沃-诺迪斯克有限公司 | Medical system comprising dual purpose communication means |
| US9173992B2 (en) * | 2006-03-13 | 2015-11-03 | Novo Nordisk A/S | Secure pairing of electronic devices using dual means of communication |
| JP2009532117A (en) | 2006-03-30 | 2009-09-10 | ヴァレリタス，エルエルシー | Multi-cartridge fluid dispensing device |
| JP5231394B2 (en) | 2006-04-19 | 2013-07-10 | アシスト・メディカル・システムズ，インコーポレイテッド | Extravasation detection device |
| EP2012852A1 (en) * | 2006-04-26 | 2009-01-14 | Novo Nordisk A/S | Skin-mountable device in packaging comprising coated seal member |
| US20070255126A1 (en) | 2006-04-28 | 2007-11-01 | Moberg Sheldon B | Data communication in networked fluid infusion systems |
| WO2007141210A1 (en) * | 2006-06-06 | 2007-12-13 | Novo Nordisk A/S | Assembly comprising skin-mountable device and packaging therefore |
| US7605710B2 (en) * | 2006-08-18 | 2009-10-20 | Fresenius Medical Care Holdings, Inc. | Wetness sensor |
| DE102006041265B3 (en) | 2006-09-02 | 2007-12-06 | Fresenius Medical Care Deutschland Gmbh | Vascular access e.g. butterfly cannula, creating device for extracorporeal blood treatment, has base body with electrically conductive contact component provided at lower side of fin pieces, where body is made of non-conductive material |
| DE102006042336A1 (en) * | 2006-09-08 | 2008-03-27 | Fresenius Medical Care Deutschland Gmbh | Device and method for monitoring access to a patient, in particular a vascular access in an extracorporeal blood treatment |
| US8579853B2 (en) | 2006-10-31 | 2013-11-12 | Abbott Diabetes Care Inc. | Infusion devices and methods |
| DK2121076T3 (en) * | 2006-12-29 | 2017-07-24 | Hoffmann La Roche | Infusion device that can be worn outside the body |
| US8152751B2 (en) | 2007-02-09 | 2012-04-10 | Baxter International Inc. | Acoustic access disconnection systems and methods |
| US8376978B2 (en) * | 2007-02-09 | 2013-02-19 | Baxter International Inc. | Optical access disconnection systems and methods |
| US10463778B2 (en) | 2007-02-09 | 2019-11-05 | Baxter International Inc. | Blood treatment machine having electrical heartbeat analysis |
| US20100063448A1 (en) * | 2007-03-06 | 2010-03-11 | Novo Nordisk A/S | Pump assembly comprising actuator system |
| MX2009010000A (en) | 2007-03-19 | 2010-03-17 | Insuline Medical Ltd | Drug delivery device. |
| WO2009081262A1 (en) | 2007-12-18 | 2009-07-02 | Insuline Medical Ltd. | Drug delivery device with sensor for closed-loop operation |
| US9220837B2 (en) * | 2007-03-19 | 2015-12-29 | Insuline Medical Ltd. | Method and device for drug delivery |
| US8622991B2 (en) * | 2007-03-19 | 2014-01-07 | Insuline Medical Ltd. | Method and device for drug delivery |
| MX2009009999A (en) * | 2007-03-19 | 2010-03-17 | Insuline Medical Ltd | Method and device for drug delivery. |
| AU2014200298B2 (en) * | 2007-03-19 | 2015-08-13 | Insuline Medical Ltd. | Method and device for drug delivery |
| US8597243B2 (en) * | 2007-04-30 | 2013-12-03 | Medtronic Minimed, Inc. | Systems and methods allowing for reservoir air bubble management |
| US7963954B2 (en) | 2007-04-30 | 2011-06-21 | Medtronic Minimed, Inc. | Automated filling systems and methods |
| US8323250B2 (en) | 2007-04-30 | 2012-12-04 | Medtronic Minimed, Inc. | Adhesive patch systems and methods |
| JP5102350B2 (en) * | 2007-04-30 | 2012-12-19 | メドトロニック ミニメド インコーポレイテッド | Reservoir filling / bubble management / infusion medium delivery system and method using the system |
| US8434528B2 (en) | 2007-04-30 | 2013-05-07 | Medtronic Minimed, Inc. | Systems and methods for reservoir filling |
| US7959715B2 (en) * | 2007-04-30 | 2011-06-14 | Medtronic Minimed, Inc. | Systems and methods allowing for reservoir air bubble management |
| US8613725B2 (en) | 2007-04-30 | 2013-12-24 | Medtronic Minimed, Inc. | Reservoir systems and methods |
| US8075908B2 (en) * | 2007-08-17 | 2011-12-13 | Anhese Llc | Apparatus and method for reducing the occurrence of post-surgical adhesions |
| US9968742B2 (en) * | 2007-08-29 | 2018-05-15 | Medtronic Minimed, Inc. | Combined sensor and infusion set using separated sites |
| US8187184B2 (en) * | 2007-09-21 | 2012-05-29 | Baxter International, Inc. | Access disconnect system with optical and other sensors |
| CN101888859B (en) * | 2007-10-31 | 2014-09-17 | 诺沃-诺迪斯克有限公司 | Non-porous material as sterilization barrier |
| US9456955B2 (en) | 2007-12-31 | 2016-10-04 | Deka Products Limited Partnership | Apparatus, system and method for fluid delivery |
| US8414563B2 (en) | 2007-12-31 | 2013-04-09 | Deka Products Limited Partnership | Pump assembly with switch |
| US8881774B2 (en) | 2007-12-31 | 2014-11-11 | Deka Research & Development Corp. | Apparatus, system and method for fluid delivery |
| US10188787B2 (en) | 2007-12-31 | 2019-01-29 | Deka Products Limited Partnership | Apparatus, system and method for fluid delivery |
| US10080704B2 (en) | 2007-12-31 | 2018-09-25 | Deka Products Limited Partnership | Apparatus, system and method for fluid delivery |
| US8900188B2 (en) | 2007-12-31 | 2014-12-02 | Deka Products Limited Partnership | Split ring resonator antenna adapted for use in wirelessly controlled medical device |
| RU2510758C2 (en) | 2007-12-31 | 2014-04-10 | Дека Продактс Лимитед Партнершип | Infusion pump assembly |
| US8986253B2 (en) | 2008-01-25 | 2015-03-24 | Tandem Diabetes Care, Inc. | Two chamber pumps and related methods |
| EP2095841B1 (en) * | 2008-02-29 | 2012-11-07 | F. Hoffmann-La Roche AG | Connection system for connecting a fluid line to a fluid reservoir |
| US9138536B2 (en) | 2008-04-01 | 2015-09-22 | Gambro Lundia Ab | Apparatus and a method for monitoring a vascular access |
| US8114043B2 (en) | 2008-07-25 | 2012-02-14 | Baxter International Inc. | Electromagnetic induction access disconnect sensor |
| US7959598B2 (en) | 2008-08-20 | 2011-06-14 | Asante Solutions, Inc. | Infusion pump systems and methods |
| US8408421B2 (en) | 2008-09-16 | 2013-04-02 | Tandem Diabetes Care, Inc. | Flow regulating stopcocks and related methods |
| US8650937B2 (en) | 2008-09-19 | 2014-02-18 | Tandem Diabetes Care, Inc. | Solute concentration measurement device and related methods |
| US8262616B2 (en) | 2008-10-10 | 2012-09-11 | Deka Products Limited Partnership | Infusion pump assembly |
| US9180245B2 (en) | 2008-10-10 | 2015-11-10 | Deka Products Limited Partnership | System and method for administering an infusible fluid |
| US8066672B2 (en) | 2008-10-10 | 2011-11-29 | Deka Products Limited Partnership | Infusion pump assembly with a backup power supply |
| US8223028B2 (en) | 2008-10-10 | 2012-07-17 | Deka Products Limited Partnership | Occlusion detection system and method |
| US8267892B2 (en) | 2008-10-10 | 2012-09-18 | Deka Products Limited Partnership | Multi-language / multi-processor infusion pump assembly |
| US8708376B2 (en) | 2008-10-10 | 2014-04-29 | Deka Products Limited Partnership | Medium connector |
| US8016789B2 (en) | 2008-10-10 | 2011-09-13 | Deka Products Limited Partnership | Pump assembly with a removable cover assembly |
| US20100100026A1 (en) * | 2008-10-16 | 2010-04-22 | Fresenius Medical Care Holdings, Inc. | Wetness sensor utilizing passive resonant circuits |
| BRPI0916125A2 (en) | 2008-11-07 | 2015-11-03 | Insuline Medical Ltd | "treatment device" |
| US8560082B2 (en) | 2009-01-30 | 2013-10-15 | Abbott Diabetes Care Inc. | Computerized determination of insulin pump therapy parameters using real time and retrospective data processing |
| EP2272559A1 (en) * | 2009-06-29 | 2011-01-12 | Unomedical A/S | Infusion Device |
| US8467972B2 (en) | 2009-04-28 | 2013-06-18 | Abbott Diabetes Care Inc. | Closed loop blood glucose control algorithm analysis |
| US20120130207A1 (en) * | 2009-04-29 | 2012-05-24 | Janisys Limited | micro-needle device and apparatus and a method for applying a micro-needle element to a site on the skin of a subject |
| WO2011008966A2 (en) | 2009-07-15 | 2011-01-20 | Deka Products Limited Partnership | Apparatus, systems and methods for an infusion pump assembly |
| EP3173014B1 (en) | 2009-07-23 | 2021-08-18 | Abbott Diabetes Care, Inc. | Real time management of data relating to physiological control of glucose levels |
| EP2724739B1 (en) | 2009-07-30 | 2015-07-01 | Tandem Diabetes Care, Inc. | Portable infusion pump system |
| US8900190B2 (en) * | 2009-09-02 | 2014-12-02 | Medtronic Minimed, Inc. | Insertion device systems and methods |
| US8932256B2 (en) | 2009-09-02 | 2015-01-13 | Medtronic Minimed, Inc. | Insertion device systems and methods |
| US8998858B2 (en) * | 2009-12-29 | 2015-04-07 | Medtronic Minimed, Inc. | Alignment and connection systems and methods |
| US9039653B2 (en) * | 2009-12-29 | 2015-05-26 | Medtronic Minimed, Inc. | Retention systems and methods |
| US8998840B2 (en) | 2009-12-30 | 2015-04-07 | Medtronic Minimed, Inc. | Connection and alignment systems and methods |
| US8858500B2 (en) | 2009-12-30 | 2014-10-14 | Medtronic Minimed, Inc. | Engagement and sensing systems and methods |
| US8435209B2 (en) | 2009-12-30 | 2013-05-07 | Medtronic Minimed, Inc. | Connection and alignment detection systems and methods |
| US9421321B2 (en) | 2009-12-30 | 2016-08-23 | Medtronic Minimed, Inc. | Connection and alignment systems and methods |
| US11497850B2 (en) | 2009-12-30 | 2022-11-15 | Medtronic Minimed, Inc. | Connection and alignment detection systems and methods |
| US20120215163A1 (en) | 2009-12-30 | 2012-08-23 | Medtronic Minimed, Inc. | Sensing systems and methods |
| WO2011082370A1 (en) * | 2009-12-31 | 2011-07-07 | Abbott Diabetes Care Inc. | Injection port device adapted for use with insulin pump |
| EP2525848B1 (en) | 2010-01-22 | 2016-08-03 | DEKA Products Limited Partnership | System for shape-memory alloy wire control |
| US9215995B2 (en) | 2010-06-23 | 2015-12-22 | Medtronic Minimed, Inc. | Sensor systems having multiple probes and electrode arrays |
| EP2604303A4 (en) * | 2010-08-13 | 2014-01-29 | Aqua Power System Japan | Liquid leakage detection system |
| EP2696918A2 (en) | 2011-04-11 | 2014-02-19 | Novo Nordisk A/S | Injection device incorporating dose monitoring |
| CN103702698A (en) * | 2011-05-26 | 2014-04-02 | 尼普洛株式会社 | Infusion pump |
| WO2013134519A2 (en) | 2012-03-07 | 2013-09-12 | Deka Products Limited Partnership | Apparatus, system and method for fluid delivery |
| US9155866B2 (en) * | 2012-09-13 | 2015-10-13 | Becton, Dickinson And Company | Luer securement device |
| US9180242B2 (en) | 2012-05-17 | 2015-11-10 | Tandem Diabetes Care, Inc. | Methods and devices for multiple fluid transfer |
| US8740865B2 (en) * | 2012-05-31 | 2014-06-03 | International Business Machines Corporation | Ostomy appliance wear time prediction |
| US9555186B2 (en) | 2012-06-05 | 2017-01-31 | Tandem Diabetes Care, Inc. | Infusion pump system with disposable cartridge having pressure venting and pressure feedback |
| CN102764466B (en) * | 2012-08-09 | 2014-04-02 | 南宁同展拓电子科技有限责任公司 | Infusion drop monitoring system on basis of sound wave vibration signal |
| DE102012017205A1 (en) * | 2012-08-31 | 2014-03-27 | Fresenius Medical Care Deutschland Gmbh | Method and device for testing sensors to be applied to the skin of a patient for the detection of fluid or moisture |
| US9750876B2 (en) * | 2012-10-09 | 2017-09-05 | Becton, Dickinson And Company | Infusion site leak detection device |
| CN103908266B (en) * | 2013-01-09 | 2015-12-02 | 北京怡成生物电子技术股份有限公司 | Miniature bodily fluid sampling device |
| US10130288B2 (en) | 2013-03-14 | 2018-11-20 | Cell and Molecular Tissue Engineering, LLC | Coated sensors, and corresponding systems and methods |
| US10405961B2 (en) | 2013-03-14 | 2019-09-10 | Cell and Molecular Tissue Engineering, LLC | Coated surgical mesh, and corresponding systems and methods |
| US9173998B2 (en) | 2013-03-14 | 2015-11-03 | Tandem Diabetes Care, Inc. | System and method for detecting occlusions in an infusion pump |
| JP6098250B2 (en) * | 2013-03-14 | 2017-03-22 | セイコーエプソン株式会社 | Liquid transport device |
| ITTO20130523A1 (en) * | 2013-06-26 | 2014-12-27 | Eltek Spa | MEDICAL DEVELOPMENT OF A LOSS OF FLUID ON A SUBJECT |
| WO2015003145A1 (en) | 2013-07-03 | 2015-01-08 | Deka Products Limited Partnership | Apparatus, system and method for fluid delivery |
| US9561324B2 (en) | 2013-07-19 | 2017-02-07 | Bigfoot Biomedical, Inc. | Infusion pump system and method |
| JP6442408B2 (en) * | 2013-09-26 | 2018-12-19 | 国立大学法人 東京大学 | Sheet covering |
| US10569015B2 (en) | 2013-12-02 | 2020-02-25 | Bigfoot Biomedical, Inc. | Infusion pump system and method |
| EP3082901B1 (en) * | 2013-12-20 | 2019-05-15 | Sanofi-Aventis Deutschland GmbH | Drug delivery device with disposable cartridge and disposable injector |
| US10279105B2 (en) | 2013-12-26 | 2019-05-07 | Tandem Diabetes Care, Inc. | System and method for modifying medicament delivery parameters after a site change |
| GB2525150A (en) * | 2014-01-30 | 2015-10-21 | Cellnovo Ltd | Therapeutic product delivery device |
| US9707336B2 (en) * | 2014-04-07 | 2017-07-18 | Medtronic Minimed, Inc. | Priming detection system and method of using the same |
| JP2017526488A (en) * | 2014-09-15 | 2017-09-14 | サノフイ | Injection device with tissue expansion detection |
| WO2016119211A1 (en) * | 2015-01-30 | 2016-08-04 | National Taipei University Of Technology | Sensor patch, system, and method for detecting fluid leakage |
| US9878097B2 (en) | 2015-04-29 | 2018-01-30 | Bigfoot Biomedical, Inc. | Operating an infusion pump system |
| US9928341B2 (en) * | 2015-11-12 | 2018-03-27 | Vivante Health, Inc. | Systems and methods for providing comprehensive care for stoma patients |
| CN105617489B (en) * | 2015-12-22 | 2018-12-18 | 宋振玉 | A kind of multifunctional tumor medicine injecting device |
| AU2016385454B2 (en) | 2016-01-05 | 2021-12-16 | Bigfoot Biomedical, Inc. | Operating multi-modal medicine delivery systems |
| JP6752267B2 (en) * | 2016-03-11 | 2020-09-09 | テルモ株式会社 | Chemical administration device |
| EP3612252B1 (en) * | 2017-04-20 | 2021-12-15 | Becton, Dickinson and Company | Insulin leakage sensor with electric control to stop insulin flow |
| CA3055793A1 (en) * | 2017-04-20 | 2018-10-25 | Becton Dickinson And Company | Infusion set with leakage indicator |
| EP3687602A4 (en) * | 2017-09-27 | 2021-06-23 | Becton, Dickinson and Company | Fluid delivery device with leak detection |
| AU2019233297A1 (en) * | 2018-03-15 | 2020-09-24 | Coloplast A/S | Methods for future operating state and related accessory devices of an ostomy system, and ostomy systems |
| WO2019200281A1 (en) | 2018-04-12 | 2019-10-17 | DiaTech Diabetic Technologies, LLC | Systems and methods for detecting disruptions in fluid delivery devices |
| WO2019209963A1 (en) | 2018-04-24 | 2019-10-31 | Deka Products Limited Partnership | Apparatus and system for fluid delivery |
| TWI791933B (en) | 2019-01-07 | 2023-02-11 | 美商伊路米納有限公司 | System and method for detecting and analyzing fluid |
| AU2021290310B2 (en) | 2020-07-15 | 2022-08-25 | Hollister Incorporated | Resistance sensor for identifying leak locations in ostomy system |
| US11311666B1 (en) | 2021-02-18 | 2022-04-26 | Fresenius Kabi Deutschland Gmbh | Modular wearable medicament delivery device and method of use thereof |
| US11464902B1 (en) | 2021-02-18 | 2022-10-11 | Fresenius Kabi Deutschland Gmbh | Wearable medicament delivery device with compressible reservoir and method of use thereof |
| US11872369B1 (en) * | 2021-02-18 | 2024-01-16 | Fresenius Kabi Deutschland Gmbh | Wearable medicament delivery device with leakage and skin contact sensing and method of use thereof |
| USD1013864S1 (en) | 2021-08-26 | 2024-02-06 | Deka Products Limited Partnership | Fluid administration apparatus assembly |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB227906A (en) | 1923-10-22 | 1925-01-22 | Auguste Escaich | Improvements in dyeing processes |
| US3399971A (en) | 1964-05-13 | 1968-09-03 | Pfizer & Co C | Medical diagnostic method |
| US4122838A (en) | 1976-08-09 | 1978-10-31 | Leonard Loren W | Body surface contour deformation sensor |
| US4239495A (en) | 1979-02-12 | 1980-12-16 | Sherwood Medical Industries Inc. | Determination of protein |
| US4619653A (en) * | 1979-04-27 | 1986-10-28 | The Johns Hopkins University | Apparatus for detecting at least one predetermined condition and providing an informational signal in response thereto in a medication infusion system |
| US4731051A (en) * | 1979-04-27 | 1988-03-15 | The Johns Hopkins University | Programmable control means for providing safe and controlled medication infusion |
| US4350155A (en) * | 1980-04-02 | 1982-09-21 | Medtronic, Inc. | Body implantable medical infusion system |
| US4378808A (en) | 1980-04-07 | 1983-04-05 | Whitman Medical Corporation | Liquid crystal infiltration sensing system |
| US4784645A (en) * | 1982-11-04 | 1988-11-15 | The Johns Hopkins University | Apparatus for detecting a condition of a medication infusion system and providing an informational signal in response thereto |
| US4685903A (en) | 1984-01-06 | 1987-08-11 | Pacesetter Infusion, Ltd. | External infusion pump apparatus |
| US4562751A (en) | 1984-01-06 | 1986-01-07 | Nason Clyde K | Solenoid drive apparatus for an external infusion pump |
| US4602249A (en) * | 1984-05-21 | 1986-07-22 | Quest Medical, Inc. | Method and apparatus for detecting leaking valves in a volumetric infusion device |
| EP0168675B1 (en) * | 1984-06-21 | 1990-04-11 | David R. Fischell | Finger actuated medication infusion system |
| US4787398A (en) | 1985-04-08 | 1988-11-29 | Garid, Inc. | Glucose medical monitoring system |
| US4755173A (en) | 1986-02-25 | 1988-07-05 | Pacesetter Infusion, Ltd. | Soft cannula subcutaneous injection set |
| US4717378A (en) * | 1986-03-31 | 1988-01-05 | Medtronic, Inc. | Methods for detecting dehydration of a biomedical hydrogel |
| US4723947A (en) | 1986-04-09 | 1988-02-09 | Pacesetter Infusion, Ltd. | Insulin compatible infusion set |
| US5153827A (en) * | 1989-01-30 | 1992-10-06 | Omni-Flow, Inc. | An infusion management and pumping system having an alarm handling system |
| US5080653A (en) | 1990-04-16 | 1992-01-14 | Pacesetter Infusion, Ltd. | Infusion pump with dual position syringe locator |
| US5176662A (en) | 1990-08-23 | 1993-01-05 | Minimed Technologies, Ltd. | Subcutaneous injection set with improved cannula mounting arrangement |
| JPH07102154B2 (en) | 1992-03-02 | 1995-11-08 | 日東紡績株式会社 | Method for quantifying 1,5-anhydroglucitol |
| ATE199604T1 (en) * | 1992-07-22 | 2001-03-15 | Health Sense Int Inc | SYSTEM FOR DETECTING ELECTRICALLY CONDUCTIVE LIQUIDS |
| US5790036A (en) * | 1992-07-22 | 1998-08-04 | Health Sense International, Inc. | Sensor material for use in detection of electrically conductive fluids |
| US5399445A (en) | 1994-04-18 | 1995-03-21 | Aer Energy Resources | Battery case leakage detector |
| US5505709A (en) | 1994-09-15 | 1996-04-09 | Minimed, Inc., A Delaware Corporation | Mated infusion pump and syringe |
| US5584813A (en) | 1995-06-07 | 1996-12-17 | Minimed Inc. | Subcutaneous injection set |
| US6057689A (en) * | 1997-08-04 | 2000-05-02 | Gynecare, Inc. | Apparatus and method for leak detection in a fluid-filled balloon useful to treat body tissue |
| AU6632600A (en) | 1999-08-20 | 2001-03-19 | Acist Medical Systems, Inc. | Apparatus and method of detecting fluid |
| US6689100B2 (en) * | 2001-10-05 | 2004-02-10 | Becton, Dickinson And Company | Microdevice and method of delivering or withdrawing a substance through the skin of an animal |
-
2000
- 2000-03-13 US US09/524,021 patent/US6461329B1/en not_active Expired - Lifetime
-
2001
- 2001-03-09 EP EP01918462A patent/EP1263488B1/en not_active Expired - Lifetime
- 2001-03-09 JP JP2001566725A patent/JP3713239B2/en not_active Expired - Fee Related
- 2001-03-09 CA CA002400689A patent/CA2400689C/en not_active Expired - Fee Related
- 2001-03-09 WO PCT/US2001/007481 patent/WO2001068163A2/en active IP Right Grant
- 2001-03-09 AU AU2001245538A patent/AU2001245538A1/en not_active Abandoned
- 2001-03-09 AT AT01918462T patent/ATE347915T1/en not_active IP Right Cessation
- 2001-03-09 DE DE60125149T patent/DE60125149T2/en not_active Expired - Lifetime
-
2002
- 2002-07-03 US US10/190,168 patent/US6752785B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001068163A3 (en) | 2002-05-23 |
| US6461329B1 (en) | 2002-10-08 |
| DE60125149D1 (en) | 2007-01-25 |
| ATE347915T1 (en) | 2007-01-15 |
| EP1263488B1 (en) | 2006-12-13 |
| DE60125149T2 (en) | 2007-11-15 |
| US20030009131A1 (en) | 2003-01-09 |
| WO2001068163A2 (en) | 2001-09-20 |
| CA2400689A1 (en) | 2001-09-20 |
| JP2003526479A (en) | 2003-09-09 |
| EP1263488A2 (en) | 2002-12-11 |
| US6752785B2 (en) | 2004-06-22 |
| JP3713239B2 (en) | 2005-11-09 |
| AU2001245538A1 (en) | 2001-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2400689C (en) | Infusion site leak detection system and method of using the same | |
| US9518813B2 (en) | Sensing systems and methods | |
| US20230145155A1 (en) | Implantable micro-electrochemical cell | |
| JP5197566B2 (en) | Determination of needle position | |
| KR100945901B1 (en) | A minimally-invasive system and method for monitoring analyte levels | |
| JP4565839B2 (en) | Tissue monitoring device for vascular injection | |
| CA2622526C (en) | Flexible sensor apparatus | |
| RU2480251C2 (en) | Modular assembly for drug infusion and analyte control | |
| CA2186886C (en) | Transcutaneous sensor insertion set | |
| CN102711898A (en) | Analyte monitoring and fluid dispensing system | |
| JP2002537566A (en) | Glucose sensor package system | |
| JP2012020177A (en) | Method and system for providing integrated medication infusion/analyte monitoring system | |
| CN110947055A (en) | Injection device | |
| CA2589257A1 (en) | Bodily fluid space entry detection | |
| JP2002536038A (en) | Holter monitor system with analyte sensor | |
| KR20010032477A (en) | Extravasation detection | |
| KR100528306B1 (en) | Minimally invasive detecting device | |
| EP3763402A1 (en) | A jacket for watertight sealing a medical device | |
| CN215584996U (en) | Monitor for oozing and leaking blood | |
| ES2920809T3 (en) | Sensor device for detecting at least one analyte in a body fluid of a user | |
| CN113995913A (en) | Monitor for oozing and leaking blood | |
| WO2023215836A2 (en) | An analyte sensor for measuring at varying depths within a user | |
| CN110876624A (en) | Analyte monitoring and automatic drug delivery system | |
| KR19990035256A (en) | Medication dispenser |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20150309 |